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FAT10 is a member of the ubiquitin-like modifier (UBL) family of proteins 
and has been implicated to play important roles such as antigen presentation, cytokine 
response, apoptosis and mitosis. Recently, our laboratory reported that the FAT10 
gene is up regulated in 90% of hepatocellular carcinomas and over-expression of 
FAT10 gene may lead to chromosomal stability.   
 As part of the studies to elucidate the mechanism behind FAT10 gene 
regulation, we identified and characterized the promoter of the FAT10 gene. We 
found that the 5’UTR, from the transcription start site to 15 bases before the start 
codon, displayed significant promoter activity. Regions upstream of the 5’UTR (from 
+26 to -1997) did not confer any promoter activity.  
 As FAT10 expression was reported to be induced by cytokines, we also 
explored the role of the FAT10 promoter in cytokine responsiveness.  We found that 
the distal promoter region, -1716 to -975, was highly responsive to interferon- γ and 
tumour necrosis factor-α with 4~5 times higher expression upon treatment with 
cytokines.  
 FAT10 promoter activity and expression is significantly repressed in KB3-1 
and HepG2 cells, which have wild-type p53, but not in p53-negative Hep3B cells.  
The role of p53 in regulating FAT10 expression was evident by the significant down-
regulation (P<0.05) of FAT10 mRNA expression and promoter activity when wild-
type p53 was transfected into p53-null Hep3B cells. Conversely, inhibiting p53 
expression through siRNA against p53 significantly enhanced FAT10 expression and 
promoter activity.  P53 was found to bind in vivo to the 5’ half-consensus sequence of 
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the p53 binding site located in the FAT10 promoter. Hence, we propose that FAT10 is 
a downstream target of p53.  
  We proceeded to investigate if the up-regulation of FAT10 expression in the 
tumors of HCC patients can be accounted for by mutations or aberrant methylation at 
the FAT10 promoter region. Through sequencing of approximately 37 HCC 
individuals and 39 normal individuals, we did not find any mutations at the FAT10 
promoter region in the tumor of the patients that could account for the differential 
expression of the tumor and adjacent normal liver tissues in HCC patients. 
Nonetheless, we identified six polymorphisms, two of which were novel. Three of 
these six polymorphisms, one in the 5’ flanking region (-616(T/C)) and two at the 
5’UTR (+82(A/G) and +104(A/G)), occurred at high frequency in both the normal 
and HCC patients. With the current data, we did not find obvious correlation between 
the polymorphisms at the FAT10 promoter region and the relative FAT10 expression 
levels in HCC patients.  Nonetheless, we recapitulated various combinations of these 
three polymorphisms and examined FAT10 promoter activity in Hep3B cell-line. We 
found that different haplotypes of SNPs at the FAT10 promoter mediate significantly 
different FAT10 promoter activities.   
 We also performed a preliminary screening of tissues from 11 HCC patients to 
examine if the methylation status at the FAT10 promoter region could account for the 
differential expression between the tumor and adjacent normal liver tissues in HCC 
patients. There was statistically significant inverse correlation between the 
methylation status and relative FAT10 expression in these HCC patients. Generally, 
the tumor tissues are less methylated which correlated with higher FAT10 expression 
in the tumor. 
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1.1 Role of Ubiquitin in posttranslational modification  
1.1.1 Ubiquitin and ubiquitylation  
Ubiquitin is a small 76 amino acids protein and is conserved in all eukarytic 
cells. Its main function is to conjugate target proteins, thereby “tagging” these protein 
for degradation via the 26S proteasome pathway (Hochstrasser, 1996a; Hochstrasser, 
1996b). Ubiquitylation, or the post-translational modification of a protein by the 
covalent attachment of one or more ubiquitin monomers, is a well-known 
multifunctional signaling mechanism that regulates many cellular processes including 
cell-cycle (Biggins et al., 1996) and apoptosis (Pickart, 2001). The specificity of 
target protein selection and the mode of ubiquitin conjugation are determined by an 
enzymatic cascade involving three enzymes: a ubiquitin-activating enzyme (E1), a 
ubiquitin-conjugating enzyme (E2), and a ubiquitin ligase (E3). In the first step, the 
conserved C-terminal glycine (Gly76) of ubiquitin is activated by E1 in an ATP-
dependent manner. Subsequently, activated ubiquitin is transferred to an active site 
containing the cysteine (Cys) residue of E2 enzyme. Catalysed by E3, ubiquitin is 
finally transferred from E2 and linked to a lysine (Lys) residue of the substrate 
through the carboxyl group of the C-terminal Gly76 (Ciechanover et al., 1980; 
Hershko et al., 1980).  
Substrates can be polyubiquitylated or monoubiquitylated and it is the mode of 
ubiquitylation that determines the fate of the tagging protein. In the case of 
polyubiquitylation, additional ubiquitin molecules are conjugated to the first one to 
form a branched chain through the lysine residue. Polyubiquitination serves many 
functions and is dependent on which lysine residues of ubiquitin the chain is linked to. 
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For example, Lys48-linked chain is the principal signal for targeting to proteasomes 
and proteolysis whilst Lys63-linked chains function in DNA repair (Hofmann and 
Pickart, 1999), endocytosis(Rotin et al., 2000), cell cycle regulation(Spence et al., 
2000) and stress response(Galan and Haguenauer-Tsapis, 1997). Monoubiquitylation 
is the process whereby a single ubiquitin peptide is bound to a substrate that functions 
as a signal for endocytosis(Hicke, 1997) and cell division(Robzyk et al., 2000).  
 
1.1.2 Ubiquitin-like protein family 
Members of the ubiquitin-like protein family contain domains that are 15% to 
60% ubiquitin at the protein level (Raasi et al., 2001). The ubiquitin-like proteins can 
be classified into two groups (Jentsch and Pyrowolakis, 2000): (a) ubiquitin domain 
protein (UDPs), for example, RAD23, BAG1, Elongin B and Gdx, which contain a 
ubiquitin homology domain but do not become covalently linked to target proteins; 
and (b) ubiquitin-like modifiers (UBLs) which can covalently conjugate target 
proteins. Examples are SUMO (small UBL modifier), which is involved with cell 
cycle regulation (Matunis et al., 1996), and ISG15, which is involved in pregnancy 
and innate immunity that includes modulating response to alpha interferon (IFN-
a)(Ritchie et al., 2004). In recent years, there have been discoveries of other UBLs 
that resemble ubiquitin in substrate conjugation and the versatility of function 
(Hochstrasser, 2000; Weissman, 2001). This includes UCRP (ubiquitin cross-reactive 
protein) and Saccharomyces cerevisiase RUB1 (related-to-ubiquitin 1), also known as 
NEDD8 in metazoans. UCRP may serve as a trans-acting binding factor directing the 
association of ligated target proteins to intermediate filaments (Loeb et al., 1994). The 
substrates of RUB1 (NEDD8) are members of the cullin family that are common 
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subunits of the multi-subunit ubiquitin protein ligases that include SCF (Skp1/cullin-
1/F-box protein), CBC (cullin-2/elongin BC) and E3s (Lammer et al, 1998; 
Liakopoulos et al., 1998; Osaka et al., 1998). Studies also showed that the 
cytoskeleton is another potential target of RUB1 (NEDD8) conjugation (Kurz et al., 
2002). The RUB1 (NEDD8) pathway may be evolved as a regulator of the ubiquitin 
system by limiting the self-ubiquitylation of E3 subunits to down-regulate E3 activity, 
or triggering a conformational switch in the ubiquitin E2-E3 complex to stimulate 
substrate ubiquitylation (Hochstrasser, 2000; Kamura et al., 1999; Read et al., 2000). 
Although most of the UBL family members were reported to attach covalently to 
other proteins via their C-termini containing the conserved Gly–Gly motifs and utilize 
similar pathways of conjugation to ubiquitin, their E1, E2 and E3 proteins are 
different (Jentsch and Pyrowolakis, 2000). 
 
1.1.3  The function of ubiquitin-like proteins  
Based on previous reports, ubiquitin-like proteins are thought to have an 
important role in many cellular processes. The UBL protein SUMO family consists of 
three members: SUMO-1, SUMO-2 and SUMO-3 (Hay, 2005). SUMO-1 is a protein 
of 101 amino acids, and is 18% identical to human ubiquitin (Yeh et al., 2000). 
SUMO-2 and SUMO-3 differ only by three N-terminal amino acids and are nearly 
50% identical to SUMO-1 (Rossi et al., 2006). SUMO-1 has been reported to have 
diverse functions including the regulation of subcellular transport, transcriptional 
regulation, chromosome segregation and cell cycle control (Hay, 2005).  For example, 
SUMO-1 has been reported to conjugate with the PML oncogene (Boddy et al., 1996; 
Muller et al., 1998) and shown to modify a number of oncoproteins like p53 and c-jun, 
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thus altering their activity (Sampson et al., 2001). The function of SUMO-2 and 
SUMO-3 is still unclear. Another UBL protein, NEDD8, which shares 57% amino 
acid identity with ubiquitin and regulates SCF ubiquitin-ligases via cullin 
modification, has been shown to be essential for cell-cycle progression in mice 
(Tateishi et al., 2001). The UDP protein, Elongin B, was found to be associated with 
the von Hippel Lindau (VHL) tumor suppressor, which positively regulates the 
“guardian of the genome” p53 gene (Watson and Irwin, 2006) in a VHL-dependent 
E3 complex (Iwai et al., 1999). Similarly, the yeast UDP protein, DSK2p, was 
reported to be involved in spindle pole body duplication (Biggins et al., 1996).  
  Dysregulation or mutation in genes coding for ubiquitin-like proteins are 
thought to be responsible for the pathogenesis of various diseases including cancer. 
For example, E3 enzymes function as the substrate recognition modules of the system, 
capable of interaction with both E2 and substrate. E3 enzymes possess either one of 
two domains: Homologous to the E6-AP Carboxyl Terminus (HECT) domain and 
Ring finger domain (Jackson et al., 2000). E3 enzymes with the HECT domain 
transfer ubiquitin directly to substrates whilst those with the ring finger protein 
domain act to facilitate the interaction between the substrate and E2 (Joazeiro et al., 
2000). Mutation of the Ring finger in the BRCA1 gene that normally functions as a 
breast and ovarian cancer-specific tumor suppressor results in an increased risk of 
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1.2  General Information about FAT10 
HLA-F Adjacent Transcript 10 (FAT10) is an 18kDa protein comprising 165 
amino acid residues. It was originally discovered through the identification of 
expressed genes encompassing the HLA-F genomic locus (Fan et al., 1996). Although 
FAT10 gene is encoded within the major histocompatibility complex (MHC) class I 
locus which is composed of many genes that play various key roles in immune 
surveillance against cancer and infectious diseases, FAT10 gene is a non-class I gene 
(Fan et al., 1996). Expression of FAT10 gene does not affect cell surface expression 
or antigen presentation of MHC class I genes (Raasi et al., 2001). Moreover, FAT10 
shows a tissue-specific distribution (Lee et al., 2003). It can be detected in a number 
of different tissues including the gastrointestinal system, kidney, lung and prostate 
gland, but not in tissues from the brain and adrenal gland. The reticuloendothelial 
system (e.g. thymus, spleen) and the gastrointestinal system show highest expression 
of FAT10 (Lee et al., 2003).   
  
1.2.1 FAT10 as a new member of UBL family 
FAT10 encodes a protein containing two tandem head-to-tail ubiquitin-like 
domains held together by short linker, which makes it different from those of other 
members of the ubiquitin family (Bates et al., 1997; Fan et al., 1996; Gruen et al., 
1996). The amino-terminal domain of FAT10 is 29% identical to ubiquitin, whereas 
the carboxyl(C)-terminal domain displays 36% identity. Like ubiquitin, FAT10 
conserves the C-terminal Gly–Gly residues. Unlike other UBLs, FAT10 is 
synthesized with a free diglycine motive at its C-terminus, which implies that it can 
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potentially become conjugated immediately after translation and folding (Hipp et al., 
2005). Furthermore, there is a conserved Lys residue in each moiety of FAT10 
analogous to Lys48 of ubiquitin, each of which may serve as a potential site for 
polyubiquitination of FAT10 (Lee et al., 2003). Evidence suggests that FAT10 may 
be covalently linked to target proteins via its C terminus in inducible FAT10 
transfectants, because, in addition to monomeric FAT10, a prominent band of about 
35 kDa was also detected using FAT10 specific antibodies. This 35 kDa band was 
found to resist boiling in sodium dodecyl sulfate (SDS) under reduced conditions and 
disappeared when the diglycine motif of FAT10 was mutated (Raasi et al., 2001). 
Hence, FAT10 may covalently conjugate via its C-terminal diglycine motif analogous 
to ubiquitin and other ubiquitin-like modifiers (Raasi et al., 2001).  
While the roles of FAT10 remain largely unknown, our understanding of how 
the FAT10 protein is degraded has become clearer. NEDD8 ultimate buster-1L 
(NUB1L) is known for its interaction with the ubiquitin-like protein NEDD8, thus 
leading to accelerated NEDD8 degradation. Through yeast two-hybrid screening, 
NUB1L was identified as a non-covalent binding partner of FAT10 (Hipp et al., 2004). 
Interestingly, it was reported that NUB1L binds to FAT10 much stronger than to 
NEDD8 and that NEDD8 cannot compete with FAT10 for NUB1L binding. The 
coexpression of NUB1L with FAT10 enhanced the degradation rate of FAT10 by 8-
fold, whereas coexpression of NUB1L with NEDD8 increased NEDD8 degradation 
rate only by 2-fold(Hipp et al., 2004). Because NUB1L was shown to bind to the 
proteasome subunit RPN10 in vitro and to be contained in 26 S proteasome 
preparations, it may function as a linker that targets FAT10 for degradation by the 
proteasome (Hipp et al., 2004). Further research showed that the ubiquitin-associated 
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domains of NUB1L are required for binding but not for accelerated degradation of 
FAT10 (Schmidtke et al., 2006).  Overexpression of the wild type FAT10, but not the 
carboxyl-terminal mutant, induced apoptosis in transfectants within 24 hours of the 
appearance of a monomeric FAT10 protein as well as several proteins of higher 
molecular weight that were not formed in the Diglycine mutant (Raasi et al., 2001; 
Schmidtke et al., 2006). It was also reported that fusion of FAT10 to the N terminus 
of the long-lived green fluorescent protein (GFP) led to its rapid degradation in HeLa 
cells (Hipp et al., 2005). Additionally, FAT10 and ubiquitin showed equal efficiency 
at targeting GFP for degradation when fused to its N terminus indicating that FAT10 
may also serve as a degradation signal (Hipp et al., 2005). Through the mutation of all 
lysines or by expression in ubiquitylation-deficient cells, the prevention of 
ubiquitylation of FAT10 did not affect FAT10 degradation. These data suggest that 
conjugation with FAT10 is an alternative ubiquitin-independent mechanism targeting 
proteins for degradation by the proteasome (Hipp et al., 2005). 
 
1.2.2 FAT10 and immune response 
Interferon-γ (IFN-γ) was first identified more than 40 years ago in activated 
lymphocyte supernatants to have a distinctive antiviral activity (Berg, 1965). It is 
encoded by a single-copy gene, generating a single 1.2kb mRNA and a polypeptide of 
166 residues (Derynck et al., 1982). Another factor, TNF-α, also known as cachectin, 
is named after its activity to cause tumour necrosis in vivo when injected into tumour-
bearing mice (Beutler and Cerami, 1988; Vilcek and Lee, 1991). TNF-α is expressed 
as a 26kDa membrane bound protein which is then cleaved by TNF-α converting 
enzyme (TACE) to release the soluble 17kDa monomer that forms homotrimers in 
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circulation (Black et al., 1997; Moss et al., 1997). IFN-γ and TNF-α play an important 
role in triggering antiviral, antiproliferative and antitumor activities (Deiss et al., 1995; 
Maciejewski et al., 1995). TNF-α was found to act synergistically with IFN-γ in MHC 
class I gene induction (Lapierre et al., 1988; Scheurich et al., 1986), and both NF-κB 
and ISRE elements  (AGTTTCNNTTTCNC/T, IFN-stimulated response elements) 
are required (Johnson and Pober, 1994). Another potential candidate for a synergistic 
binding is IRF-1, which is strongly supported by studies in human cells (Drew et al., 
1993; Johnson and Pober, 1994).  
FAT10 gene is encoded in the MHC class I locus (Fan et al., 1996), which is 
known to encode many important genes to govern aspects of immune response. 
However, FAT10 is a non-MHC class I gene. Initially, FAT10 cannot be detected in a 
large panel of human tissues except for two Epstein-Barr (EBV)-transformed B cells 
(Fan et al., 1996). Later it was known that expression of FAT10 was not linked to 
EBV but rather to maturation of B cells. This suggested that FAT10 might play a role 
in antigen presentation (Bates et al., 1997). Interestingly, ISG15, another ubiquitin-
like protein, which also consists of two ubiquitin-like domains, demonstrates IFN-α 
and -β responsiveness (Korant et al., 1984).  Later, it is reported that FAT10 can be 
synergistically induced by IFN-γ and TNF-α rapidly in Sw620 colon carcinoma cells, 
and this process is independent of protein synthesis but dependent on proteasome 
activity (Raasi et al., 1999). Very recently, it was reported that the ubiquitin-like 
protein FAT10 is one of the most up regulated genes in HIV-infected cells (renal 
tubular epithelial cells, RTEC)(Ross et al., 2006). FAT10 expression was found to be 
induced after infection of RTEC by HIV-1 and that expression of FAT10 induces 
apoptosis in RTEC in vitro. It was also found that inhibition of endogenous FAT10 
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expression abrogated HIV-induced apoptosis of RTEC (Ross et al., 2006). These 
results suggest a novel role for FAT10 in viral immuno-response and epithelial 
apoptosis. 
It was also recently reported that FAT10 knockout mice showed a high 
sensitivity to endotoxin challenge and its lymphocytes were more prone to 
spontaneous apoptotic death. These results indicate that FAT10 may act as a survival 
factor (Canaan et al., 2006) 
 
1.2.3 FAT10 and tumorigenesis 
1.2.3.1 FAT10 is overexpressed in tumour tissue 
The UBL family is implicated to play important roles in cell-cycle control or 
apoptosis through modification of target genes (Jentsch and Pyrowolakis, 2000). The 
dysregulated cell-cycle control or apoptosis is usually the major cause of 
tumorigenesis. Our laboratory found that FAT10 is associated with heptocellular 
carcinoma or other cancers. Northern blot analysis revealed upregulation of FAT10 
expression in the tumors of 90% of HCC patients, compared to the adjacent non-
tumorous tissue. Furthermore, In situ hybridization as well as immunohistochemistry 
utilizing anti-FAT10 antibodies localized highest FAT10 expression in the nucleus of 
HCC hepatocytes rather than the surrounding immune and non-HCC cells (Lee et al., 
2003). In addition to HCC, our laboratory also found FAT10 to be consistently 
upregulated in the tumors of patients with cancers of the gastrointestinal tract and 
female reproductive system. FAT10 was also found to be upregulated in the single 
cervical cancer, single pancreatic cancer and two intestinal cancer samples (Lee et al., 
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2003). Our laboratory further demonstrated that FAT10 overexpression in cancers is 
unlikely to be due to the general increase in protein synthesis or a general 
immune/inflammatory response to cancer. 
 
1.2.3.2 FAT10 and the chromosomal stability 
Chromosome changes, referred to as chromosome instability (CIN), occur 
frequently in cancers (Lengauer et al., 1998). Genes that are involved in the 
condensation of chromosomes, cohesion of sister chromatids, formation of 
microtubules, and kinetochore are usually responsible for CIN in human cancers 
(Lengauer et al., 1998; Nowak et al., 2002). CIN can be classified in two forms: 
structural instability and numerical instability (aneuploidy). Aneuploid CIN cells, a 
hallmark of cancer, is usually associated with aggressive tumour behavor and a poor 
prognosis (Michel et al., 2001). Defects in the mitotic checkpoint have been 
correlated with CIN in human cancer cells (Cahill et al., 1998). Mitotic arrest-
deficient 2 (MAD2) is a key mitotic spindle checkpoint protein that ensures that all of 
the chromosomes are properly attached to the mitotic spindle before the onset of 
anaphase, otherwise, it will arrest cells in mitosis (Li and Benezra, 1996). MAD2 
arrests cells in metaphase by associating with the anaphase-promoting complex (APC), 
thereby inhibiting its ubiquitin ligase activity (Fang et al., 1998; Li et al., 1997). As a 
result, anaphase is delayed until all of the kinetochores are attached by microtubules 
and the chromosomes are properly aligned along the metaphase plate (Shah and 
Cleveland, 2000; Yu, 2002).  Deletion of one MAD2 allele has been reported to result 
in a defective mitotic checkpoint in both human colon cancer cells and murine 
primary embryonic fibroblast (Michel et al., 2001).  
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The reduced expression of MAD2 gene also resulted in loss of mitotic 
checkpoint control in the G2-M phase of the cell cycle in response of microtubulin 
disruption in ovarian cancer cells (Wang et al., 2002), breast cancer (Li and Benezra, 
1996) and NPC cells (Wang et al., 2000). Furthermore, deletion of one MAD2 alelle 
has been reported to develop high rates lung tumor after long latencies (Michel et al., 
2001) in mouse, suggesting that MAD2 haplo-insufiency might contribute to CIN and 
tumorigenesis. Aberrant interaction of MAD2 with other proteins may also deregulate 
the checkpoint function of MAD2. For example, by binding to MAD2, overexpression 
of CMT2 (caught by MAD2) induces premature entry into anaphase without 
chromosome segregation (Gorbsky et al., 1998). By using the yeast two-hybrid 
system, FAT10 was identified to be another protein that binds to MAD2 
noncovalently (Liu et al., 1999). Recently our laboratory showed that FAT10 interacts 
with MAD2 during mitosis and overexpression of FAT10 can significantly reduce the 
localization of MAD2 at the kinetochore during prometaphase stage of the cell cycle, 
thus resulting in an abbreviated mitotic phase (Ren et al., 2006). Furthermore, FAT10 
overexpression also results in greater escape from mitotic arrest and more 
multinucleate cells upon prolonged mitotic arrest under nocodazole treatment than 
parental cells. Importantly, our laboratory demonstrated that over-expression of 
FAT10 protein results in cells with more variable chromosome number, a classical 
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1.3 Research objectives  
 The primary objective of this thesis is to understand the regulation of the 
FAT10 gene expression at the transcript level and to evaluate if 
mutations/polymorphisms or differential methylation at the FAT10 promoter can 
account for the aberrant over-expression of FAT10 in the tumors of HCC patients.  
The following are the specific aims that help address the primary objective of this 
study. 
 
Specific Aim 1:  Isolate and Characterize the Promoter of the FAT10 Gene  
FAT10 gene comprises only two exons with an intervening 3.6kb intron and 
an upstream putative promoter region (Fig. 1). The 5’UTR resides in exon 1.   To 
isolate and characterize the promoter of the FAT10 gene, an initial in silico analysis 
was performed to delineate the putative promoter region as well as to identify various 
putative transcriptional binding sites. Various regions upstream either the 
transcription start site (TSS) or the translation start site (TLSS) was cloned into a β-
galactosidase (β-gal) reporter construct to evaluate the promoter activity of the 
various constructs in various cell-lines as well as under various conditions. This 
construct also incorporates the enhanced green fluorescent protein (EGFP) gene for 
normalization against differences in transfection efficiencies. As FAT10 expression 
was reported to be induced by the cytokines IFN-γ and TNF-α, the approximate 
region of the FAT10 promoter that plays a role in the responsiveness to these 
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Specific Aim 2:  Determine if p53 plays a role in the regulation of FAT10 at the 
transcript level. 
Interestingly, while characterizing the FAT10 promoter activity in various 
cell-lines, we observed that the FAT10 promoter activity is significantly higher in the 
p53-negative (p53-/-) cell-line, Hep3B, than in the p53-positive (p53+/+) cell-line, 
HepG2. Since dysregulation of p53 is a hallmark of cancer, we proceeded to 
determine if p53 in fact plays a role in the regulation of the FAT10 gene expression at 
the transcript level. Constructs carrying either the wild-type (wt) p53 gene under the 
constitutive CMV promoter or vector control was introduced into p53-/- Hep3B cell-
line and the endogenous FAT10 expression was determined using reverse-
transcription real-time PCR. We also determined the FAT10 promoter activity in p53-
/-
 Hep3B cell-line when either control or wt p53 was introduced. To demonstrate the 
reversal of the effect of p53 on FAT10 promoter activity, siRNA against p53 or 
siRNA against a random sequence with no known homology to human, mouse or rat 
was also introduced and FAT10 promoter activity was determined.  We also 
attempted to delineate the region of the FAT10 promoter that confers responsiveness 
of the FAT10 promoter to p53. In silico analyses were also performed to identify 
putative p53 binding sites at the FAT10 promoter. To determine if p53 binds to this 
consensus site to repress FAT10 expression in cells, in vivo DNA 
immunoprecipitation assay was performed. Additionally, we utilized chromatin 
immunoprecipitation (ChIP) to evaluate if p53 binds the chromatin region around the 
p53 consensus site of the endogenous FAT10 promoter in vivo. 
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Specific Aim 3:  Evaluate if mutations/polymorphisms or differential methylation at 
the FAT10 promoter can account for the aberrant over-expression of FAT10 in the 
tumors of HCC patients. 
 Our lab has previously reported that the expression of the FAT10 gene is up-
regulated in greater than 90% of HCC patients (Lee et al., 2003). To determine 
whether there are mutations within the FAT10 promoter that can account for the 
aberrant over-expression of the FAT10 gene in the tumors of HCC patients, we 
sequenced approximately 1.3 kb of the FAT10 promoter region in tumors as well as 
adjacent non-tumorous liver tissues from 37 HCC patients. We did not identify any 
somatic mutations at the FAT10 promoter region in the tumors of HCC that could 
explain the over-expression of the FAT10 gene expression. Nonetheless, we identified 
six single nucleotide polymorphisms (SNPs) occurring both in the tumor and adjacent 
non-tumorous tissues of these HCC patients. Two of these polymorphisms were novel.  
We computationally inferred the haplotype of these six polymorphisms and 
recapitulated these SNP haplotypes in vitro in the promoter-reporter (β-gal) system to 
determine the effects of the different SNP haplotypes on FAT10 promoter activity.  
We proceeded to explore if the distribution of these SNPs in HCC was different from 
that of non-HCC individuals. Unfortunately, as we were unable to obtain the blood 
samples of HCC patients, we assumed that the genotypes of SNPs in the blood are the 
same as those in those in the tumors/adjacent non-tumorous liver tissues which are the 
same.  Genotypes of these SNPs were also determined from the blood of race-, 
gender- and age-matched individuals with no history of cancers. Finally, we also 
determined if different SNP-haplotypes are correlated with differences in FAT10 gene 
expression in HCC patients. 
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Aberrant methylation in the promoters of cancer-related genes has been 
reported to be associated with transcriptional inactivation (Baylin et al., 1998; Jones 
and Laird, 1999). Hence we also examined if there were abnormal methylation at the 
promoter of the FAT10 gene that may explain its over-expression. To examine the 
methylation status at the promoter of the FAT10 gene, we initially utilized in silico 
approaches to identify CG dinucleotides and to identify putative binding sites that 
may reside at these CG dinucleotides. We then utilized methylation-specific 
sequencing to determine the methylation status at the different CG dinucleotides in 
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2.1 Background  
FAT10, a new member of UBL family, contains two ubiquitin-like domains 
joined by a short linker and is 29% identical to ubiquitin at its N-terminus and 36% 
identical at the C-terminus. FAT10 is encoded in the major histocompatibility 
complex (MHC) class I locus which is composed of genes that play various key roles 
in immune response, but FAT10 gene is a non-class I gene (Fan et al., 1996).  
As a novel gene, the functions of FAT10 are only beginning to be elucidated. 
It was reported that FAT10 play a role in cell-cycle regulation suggested by its ability 
to bind to MAD2, a spindle checkpoint protein (Liu et al., 1999). Our lab recently 
reported that the FAT10 gene is up-regulated in various cancers (Lee et al., 2003) and 
is involved in regulation of chromosomal stability (Ren et al., 2006) implicating its 
role in tumorigenesis. It was also reported that FAT10 is highly expressed in dendritic 
cells and mature B cells (Bates et al., 1997) and can be synergistically induced by the 
IFN-γ and TNF-α cytokines (Raasi et al., 1999) suggesting a role of FAT10 in 
immune response.  
To elucidate the mechanism of FAT10 gene regulation, we isolated and 
characterized the promoter of FAT10. Interestingly, we found significant promoter 
activity in the 5’ untranslated region (UTR) (+1 bp to +209 bp) of the FAT10 gene but 
no promoter activity in regions upstream of the 5’UTR alone (from +26 bp to -1997 
bp).  Region -975 to +209 conferred maximum promoter activity. We also identified 
the region from –975 to –1997 as the domain of FAT10 promoter that is responsive to 
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2.2 Materials and Methods   
2.2.1  Cell lines and Transfection 
  The following cell-lines were used in this study:  KB3-1, a subclone of a HeLa 
cell-line, HepG2, a hepatocellular carcinoma (HCC) cell-line with normal p53, 
Hep3B, another HCC cell-line but with its p53 deleted and HCT116, a colon cancer 
cell line.  
For KB-3-1 cell line, HCT116 cell line and Hep3B cell line, calcium-
phosphate co-precipitation method was utilized to do the transfection. Cells were 
seeded in six-well plates at the concentration of 1.5 x105 cells / well and incubated for 
24 hours until the cells were 30-40% confluent. These cells were then transfected with 
8µg of plasmid DNA via calcium-phosphate co-precipitation method (Chen and 
Okayama, 1987). Forty-eight hours after transfection, cells were harvested for β-
galactosidase kinetic assay analyses and EGFP fluorescence measurement. For 
HepG2 cell line, SuperfectTM Transfection Reagent (Qiagen) was utilized to improve 
the transfection efficiency according to the manufacturer’s protocol.  
β-galactosidase activity was assayed using CPRG (chlorphenol red-β-D-
galactopyranoside) as substrate in a kinetic assay at 570 nm with a SpectraMAX 
PLUS microplate reader (Molecular Devices), while EGFP fluorescence was 
quantitated at 509nm using a SpectraMAX Gemini microplate reader (Molecular 
Devices) after excitation at 488nm. The β-galactosidase activity was normalized 
against the EGFP activity to correct for differences in transfection efficiencies. 
 
2.2.2  Reverse Transcript PCR 
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Total RNA from cells was isolated using the TRI-REAGENT (Mrcgene). 1 ml 
TRI-REAGENT was added to 35mm diameter dish and the cell lysate was passed 
through a pipette for several times. The total cell lysate was then transferred to a 2ml 
tube and centrifuged at 5000 rpm for 10sec. 0.2ml chloroform was added to the cell 
lysate and the contents in the tube was mixed well by shaking vigorously for 15 secs. 
The mixture was then incubated at room temperature for 2-3 mins and then 
centrifuged at 12000g (11000 rpm) for 15mins at 4oC. The solution of aqueous phase 
was collected and mixed with 0.25ml of isopropanol and 0.25ml of high salt solution 
(0.8M Sodium citratae in 1.2 M NaCl). The whole mixture was incubated at room 
temperature for 10 min and centrifuged at 13000 rpm for 10 min at 4oC to precipitate 
the total RNA. Total RNA pellet was washed with 1 ml of 75% ethanol and briefly 
air-dried and stored at –70oC.  
cDNA was synthesized from total RNA using Superscript II reverse 
transcriptase (Invitrogen) as per manufacturer’s instructions. In a 26µl reaction, 2µg 
total RNA, 2µl primer (50pmol/µl, nucleotide sequence is 5’-
GGCCACGCGTCGACTAGTACTTTTT TTTTTTTTTTTT-3’) and 2µl dNTPs 
(10mM) were added and mixed well. The mixture was incubated at 75oC for 15 
minutes and immediately incubated on ice for 5 minutes. Then the mixture was 
divided into two tubes: one tube containing 21µl is designated as the sample; the other 
tube containing 5µl of the mixture is designated as the control. The following reagents 
were added into the 21µl sample and mixed: 6.4µl of 5x Superscirpt II buffer, 1.6µl of 
Superscript II reverse transcriptase (Invitrogen, 200U/µl), 3.2µl (0.1M) of DTT. The 
total reaction volume is 32µl. As for control, the following reagents were added and 
mixed: 1.6µl 5x Superscirpt II buffer, 0.8µl (0.1M) of DTT and 0.9µl DEPC H2O. The 
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total volume for control is 8µl. These mixtures were incubated at 42oC for 1 hour and 
70oC for 15 minutes then put on ice immediately. The cDNA was stored at –70oC for 
future use. 
Reverse transcript PCR (RT-PCR) was performed in a Thermal Cycler 
(Biometra). Amplification reactions comprise 25ng of cDNA template, 0.25 pmol/ml 
each of the forward and reverse primers for the various genes and 2µl of 10x PCR 
reaction buffer and 1unit of Hotstart polymerase (Qiagen) in a total volume of 20 µl. 
The primers for the various genes are as follows: FAT10 (F: 
5’CAATGCTTCCTGCCTCTGTG, R: 5’TGCCTCTTTGCCTCATCACC). β-actin: 
(F: 5'ATGTTTGAGACCTTCACACC, R: AGGTAGTCAGTCAGGTCCCGGCC). 
For amplification of the FAT10 transcript, its cDNA was denatured at 95oC for 15 
min followed by 30 cycles of amplification at 95oC for 30 sec, 64oC for 30 sec and 
72oC for 30 sec, then a final extension at 72o C for 5 mins; For amplification of the β-
actin transcript, its cDNA was denatured at 95oC for 15 min followed by 30 cycles of 
amplification at 95oC for 30 sec, 55oC for 30 sec and 72oC for 30 sec, then a final 
extension at 72o C for 5 mins. 
 
2.2.3  DNA sequencing reaction 
DNA sequencing was performed using an ABI PRISM 3100 Genetic Analyzer 
(Applied Biosystem). A 15µl sequencing reaction contained 10ng of purified PCR 
product, 3.2 pmol of sequencing primer, 1µl of BigdyeTM Terminator Cycle 
Sequencing Ready Reaction (Applied Biosystem). The cycling program of sequencing 
was performed as 30 cycles with an initial rapid thermal ramping to 96oC for 10sec, 
followed by annealing at 50oC for 5 sec, and an extension at 60oC for 4mins. The 
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DNA was pelleted by ethanol precipitation and air-dried. 12µl of HiDi (Applied 
Biosystem) was added to dissolve the pellet and the resulting solution was pipetted 
into a 96 well plate for sequencing. 
 
2.2.4 Determination of FAT10, p53 and β-actin protein levels 
Cells were lysed using Reporter Lysis bufferTM as per manufacturer’s 
instructions. Whole cell lysates were electrophoresed on a 10% SDS-polyacrylamide 
gel and transferred onto a PVDF membrane (BioRad).  Proteins on the membrane 
were then probed with either anti-p53 antibody (1:5,000) (mouse monoclonal IgG2a) 
(Santa Cruz Biotechnology), anti-FAT10 antibody (1:4,000) (rabbit polyclonal) (Lee 
et al., 2003) or anti-β-actin antibody (1:4,000) (goat polyclonal) (Santa Cruz 
Biotechnology) and either horseradish peroxidase conjugated goat anti-mouse, goat 
anti-rabbit or rabbit anti-goat secondary antibodies (1:5,000) (Pierce Biotechnology).  
Blots were then visualized using SuperSignalTM Duro Reagent (Pierce 
Biotechnology). 
 
2.2.5  Identification of promoter region in the FAT10 gene 
As no putative promoter region in the FAT10 gene can be predicted using in 
silico strategies with programs from websites http://bimars.dcrt.nih.Gov/ 
molbio/proscan/ and http://www.cbs.dtu.dk/services/Promoter/, various regions 
upstream of the translation start site (TLSS) or the reported transcription start site 
(TSS) (Liu et al., 1999) were cloned to test for promoter activity. Polymerase chain 
reaction (PCR) was performed using human genomic DNA and primers (Table 1) 
  
 
Chapter II       Isolation and Characterization of the Promoter of the FAT10 Gene                                24  
designed according to sequences on chromosome 6p21 (Accession number: 






FAT10 gene was inserted into an expression vector (pFAT10-EGFP) in which the 
putative FAT10 promoter drives the β-galactosidase (β-gal) reporter gene while the 
constitutive cytomegalovirus (CMV) promoter drives the enhanced green fluorescent 
protein (EGFP) reporter gene (Fig. 2). Site directed mutagenesis was employed to 
mutate the putative TATA box (FAT (+1/+209)TAT-Mut or FATprom TATA-Mut) 
using the strategy as shown in Fig. 3. All constructs were sequence verified to exclude 















Table 1. Oligonucleotides for amplification of different length of 
fragments upstream of the transcription start site (TSS) or 
translation start site (TLSS) of FAT10 gene   
  
 



































































































































































































































































































































































































































































































































































































































































Figure 3. Strategy for mutagenesis of the TATA box in FAT10 
promoter region.  
The upper panel shows the construct for analysis of FAT10 promoter 
activity: The various putative FAT10 promoters drive the β-galactosidase 
(β-gal) gene while the constitutive cytomegalovirus (CMV) promoter 
drives the enhanced green fluorescent (EGFP) gene to normalize for 
transfection efficiency. The bottom panel shows the primer and strategy 
for generating the TATA-mutant constructs.  Primers FAT (-975)-F 
(Table 1) and FATmutTATA-R were utilized to generate the 
FATpromTATA-Mut construct while primers FAT(+1)-F (Table 1) and 
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(http://www.genomatix.de/) was utilized to predict putative transcription factor 
binding sites. 
2.2.6  Identification of IFN-γ and TNF-a responsive domain in FAT10 promoter 
region  
The three constructs that were used to analyse the responsive domain of TNF- 
α and IFN-γ in FAT10 promoter region are FAT (+1/+209), FATProm (from –975 to 
+209) and FAT (-1997/+209)(see Fig. 4). These constructs were transfected into 
Hep3B cells in 6-well plates using Calcium phosphate co-precipitation method (Chen 
and Okayama, 1987). Twenty-four hours after transfection, cells were induced by 
various concentration of TNF-α or IFN-γ (Roche) as described in results section. The 
induced cells were harvested 30 hours later after cytokine treatment. β-galactosidase 
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2.3  Results 
2.3.1  FAT10 promoter resides at the 5’UTR 
To better understand the regulation of FAT10 gene expression, we proceeded 
to identify the promoter of FAT10. We were unable to identify the putative promoter 
region using in silico strategies.  We thus introduced various regions upstream of the 
transcription start site (TSS) and translation start site (TLSS) of the FAT10 gene into 
a reporter construct (Fig.2) and quantitated its promoter activity.  As shown in Fig 4, 
regions from around the TSS (+26 bp) to -1997 bp upstream the TSS (constructs FAT 
(-975/+26), FAT (-1716/+26) and FAT (-1997/+26)) did not display significant 
promoter activity.  Promoter activity was only evident when more of the 5’UTR 
region (from +116) of FAT10 was included (constructs FAT (-366/+116), FAT (-
975/+116), FAT (-1716/+116) and FAT (-1997/+116)). More than two fold 
enhancement of promoter activity was observed when nearly the entire 5’UTR (till 15 
bp before the TLSS) was included (constructs FAT (-366/+209), FATprom, FAT (-
1716/+209) and FAT (-1997/+209)) compared to when only partial 5’UTR was 
included (constructs FAT (-366/+116), FAT (-975/+116), FAT (-1716/+116) and FAT 
(-1997/+116), respectively).  Significantly, the entire 5’UTR alone was able to confer 
significant promoter activity (construct FAT (+1/+209)). Even partial 5’UTR is 
capable of mediating significant promoter activity with region +116 to +209 
(construct FAT (+116/+209)) conferring higher FAT10 promoter activity compared to 
region +1 to +116 (construct FAT (+1/+116). Maximum promoter activity was 
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FATprom). Curiously, construct FAT (-1235/+209) resulted in a significantly reduced 
promoter activity compared to either constructs FAT (-975/+209) or FAT (-
1716/+209) suggesting that regions between -1235 and -975 may contain a silencer 
element. 
Putative transcription binding sites were identified using the MatInspector 
program in the 1.18kb region of FAT10 gene (Fig.5, construct FATprom) that 
conferred the highest promoter activity (Fig. 4).  A TATA box residing between +163 
bp to +177 bp was identified in this fragment.  However, this TATA box is not 
essential since significant promoter activity was observed when this region was 
mutated (Fig 4, constructs FATprom TATA-Mut and FAT (+1/+209) TATA-Mut) or 
deleted (Fig. 4, constructs FAT (+1/+116), FAT (-366/+116), FAT (-975/+116), FAT 
(-1716/+116) and FAT (-1997/+116)). Nonetheless, the TATA box play a role in 
enhancing FAT10 promoter activity since mutation of the TATA box (Fig. 4: 
compare constructs (FAT (+1/+209) and FAT (+1/+209) TATA-Mut or FATprom 
and FATprom TATA-Mut) or deletion of region encompassing the TATA box 
resulted in significantly lower promoter activity (Fig. 4: compare constructs FAT (-
975/+116) with FAT (-975/+209) or FAT (-1716/+116) with FAT (-1716/+209) or 
FAT (-1997/+116) with FAT (-1997/+209)). Other potentially interesting binding 
sites include those that play a role in IFN (e.g. IRF-1, IRF-2 and STAT-1), TNF (e.g. 
NFκB) (Boehm et al., 1997) and retinoid (e.g. MZF-1) responsiveness.  The existence 
of these responsive sites is consistent with observations that the expression FAT10 
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2.3.2 The responsive domain of the FAT10 promoter to TNF-α and IFN-γ resides 
in the region upstream of FAT10 promoter  
To ascertain which domain of the FAT10 promoter was responsive to TNF- α 
and IFN-γ, three FAT10 promoter constructs FAT (+1/+209), FAT (-975/+209) and 
FAT (-1997/+209) were used to study the inducibility of FAT10 promoter to TNF-α 
and IFN-γ. As showed in Fig.6, neither the core promoter (construct FAT (+1/+209)) 
nor construct FAT (-975/+209) which demonstrated the highest promoter activity 
respond significantly to either TNF-α or IFN-γ induction. However, FAT (-
1997/+209), which contains the 5’-flanking region upstream of position -975bp, 
showed 4~5 times higher activity compared to that without cytokine induction. From 
the data in Fig.6, we can conclude that the IFN-γ and TNF-α responsive domain lies 
upstream of the –975bp site 
Since Raasi et al. reported that IFN-γ and TNF-α can induce FAT10 
expression in cells synergistically, we further explored whether the addition of both 
the cytokines would result in synergistic increase in FAT10 promoter activity. As 
shown in Fig.7, no synergistic activation of the FAT10 promoter activity was 
observed when both IFN-γ and TNF-α were added simultaneously. In fact, the 
induction was simultaneously reduced when both the cytokines were added. Although 
the promoter activity when both cytokines were added was significantly higher 
(p<0.05) than the cells with no induction, the activity was lower (p<0.01) than when 



















































































































































































































































































































































































































































































































































































































































Figure 7. FAT10 promoter cannot be induced by IFN-γ and TNF-α 
Synergistically. 
 FAT(-1997/+209) was induced by IFN-γ and TNF-α together. The 
working concentration of IFN-γ and TNF-α are 200U/ml and 500U/ml 
respectively. MDR promoter was utilized as control which showed no 
response to IFN-γand TNF-α. The activity of FAT10 promoter was 
measured by normalized β-gal activity from at least 3 different 
experiments (mean + SE) in Hep3B cells. * denotes statistically different 
(p<0.05) between uninduced cells and cells induced with IFN-γ and TNF-
α together. ** denotes statistically different (p<0.01) between uninduced 
cells and cells induced with either IFN-γ or TNF-α respectively. # 
denotes statistically different (p<0.01) between cells induced with either 
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2.3.3 FAT10 promoter activity is different in different cell lines  
We proceeded to examine the promoter function of FAT10 in different cell-
lines including KB3-1, HepG2 and Hep3B using the constructs FAT (-1716/+116), 
FATprom and FAT (-1997/+209). As evident in Fig 8A, the FAT10 promoter activity 
using all 3 constructs was significantly lower in KB3-1 and HepG2 cells compared 
with Hep3B cells. Similarly FAT10 expression, as determined by RT (reverse 
transcribed)-PCR and western blot, was lower in KB3-1 and HepG2 compared to 
Hep3B cells (Fig. 8B). One feature that distinguishes KB3-1 and HepG2 cells from 
Hep3B cells is the p53 status. The former 2 cell-lines have normal functioning p53 
while p53 in Hep3B cells is deleted (Fig. 8B) (Bressac et al., 1990; Stahler and 
Roemer, 1998). These results suggest that p53 may play a role in regulating FAT10 



















































































































Figure 8. FAT10 promoter is more active in some cell-lines than 
others.   
(A) Normalized promoter activity of FAT10 from at least 3 separate 
experiments (mean + SE) in HepG2, KB3-1, and Hep3B cells containing 
constructs FAT(-1716/+116), FATprom and FAT(-1997/+209). (B) upper 
two panels show results of RT–PCR of the FAT10 and control β-actin 
genes in these three cell lines,whereas the lower three panels show results 
of Western blot analyses using anti-FAT10, anti-p53 and control anti-β-
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2.4  Discussion 
To immunologists, FAT10 is an interesting molecule as it may potentially play 
a role in immune regulation. FAT10 gene is localized to the telomeric end of the 
cluster of human major histocompatibility complex (MHC) class I (Fan et al., 1996) 
genes. In addition, it is expressed in dendritic cells and mature B cells (Bates et al., 
1997) and can be synergistically induced by the IFN-γ and TNF- α cytokines (Raasi et 
al., 1999). Although the FAT10 gene resides at the telomeric end of the MHC class I 
genes, it was reported not to be a member of this class of genes. In this study, we 
showed that the promoter architecture of the FAT10 gene (Fig. 5 and Fig. 6 upper 
panel) is quite unlike the promoters of MHC class I genes. It contains a single rather 
than 2 NFκB sites upstream the interferon-stimulated response elements like the IRF-
1 and IRF-2. Furthermore, it does not contain the site-α or enhancer B element 
(inverted CCAAT box) commonly seen in MHC I genes (van den Elsen et al., 1998).  
To better understand the role of FAT10 in immune regulation and 
tumorigenesis, we identified and characterized its promoter and carried out a series of 
experiments to reveal the regulation of FAT10 gene. We found that the core promoter 
region of the FAT10 gene resides entirely within the 5’UTR. Regions upstream the 
5’UTR (exon 1) alone does not confer any promoter activity (Fig. 4).  Basal promoter 
activity residing entirely in exon 1 was also reported in a few other genes including 
the SCA2 (Aguiar et al., 1999) and TIMP-1 (Clark et al., 1997) genes.  Although the 
consensus sequence for a TATA box was identified in the promoter of FAT10 (Fig. 
5), this box was found not to be essential for promoter activity but to play a role in 
enhancing its activity.  
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For a better understanding of FAT10 in immune response, we proceeded to 
localize the domains in the FAT10 promoter that are responsive to IFN-γ and TNF-α.  
We found that domain in FAT10 promoter that is responsive to both IFN-γ and TNF-
α lies between –975bp to -1997. Constructs that included the region, similar to earlier 
reports (Liu et al., 1999; Raasi et al., 1999), resulted in 4-5 times increased promoter 
activity when IFN-γ or TNF-α are added. Otherwise, neither of the two cytokines 
have any effect on the promoter activity. As shown in Fig.1, several important binding 
sites of IFN-γ or TNF-α responsive factors, such as two STAT1 binding sites and 
three NF-kB binding sites, were observed in the region between –975 and -1997. One 
function of NF-kappaB in tumor cells is the promotion of cell growth and cell survival 
through the induction of target genes, whose products promote cell division and 
inhibit apoptosis (Yoshimura, 2006). STAT1 is generally believed to be an anti-
oncogene because it promotes apoptosis through p53, but it could promote 
inflammation-mediated tumor development by enhancing tissue injury, remodeling, 
fibrosis and inflammation. In addition, NF-kappaB and STAT1 are important 
transcription factors that induce inflammatory mediators from inflammatory cells, 
especially macrophages (Yoshimura, 2006). TNF-α has been reported to induce 
chromatin instability (Beyne-Rauzy et al., 2004). Our lab previously reported that 
FAT10 is overexpressed in HCC and other cancers (Lee et al., 2003) and 
overexpreesion of FAT10 leads to chromatin instability (Ren et al., 2006). Hence this 
observation that FAT10 promoter is induced by TNF-α suggests that one of the 
mechanisms that TNF-α induces chromatin instability may be through FAT10. 
We also found that 5’ UTR of FAT10 promoter is not essential to cytokine 
response, although it also contains IFR-1 and NF- kappaB binding sites. From Fig 6, 
  
 
Chapter II       Isolation and Characterization of the Promoter of the FAT10 Gene                                39  
we can see that the construct FAT (-975/+209) which contains full length 5’UTR 
containing both binding sites did not show significant response to IFN-γ and TNF-α 
induction.  
  However, one aspect of our study differed from previous reports (Raasi et al., 
1999). Although it is reported that FAT10 is synergistically inducible by IFN-γ and 
TNF-α in SW620 cells with a much higher (six times) expression level compared to 
single cytokine induction (Raasi et al., 1999), our data showed that IFN-γ and TNF-α 
could not synergistically induce the FAT10 promoter (Fig. 7). In fact, the induction 
was less than when either of the cytokines was added alone. This may be due to the 
two possible reasons. First, the Hep3B cell line used in our experiment may not be 
some of the key factors for synergism found in colon tumor cell Sw620. Second, most 
genes that are synergistically inducible by IFN-γ and TNF-α contain an ISRE as well 
as a NF-κB site in their promoter (Hardaker et al., 2004). However, the 2.2kb of the 
promoter region that we cloned did not include ISRE site.  
Interestingly, we observed different promoter activity in different type of cells 
(Fig. 8A). FAT10 promoter showed a highest activity in Hep3B cells compared with 
other two cell lines, HepG2 and KB3-1. One of the major differences between Hep3B 
and the other two cell lines is the status of p53. Since dysregulation of p53 is a 
hallmark of cancer, we proceeded to determine if p53, in fact, plays a role in the 
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3.1  Background 
Dysregulation of cell-cycle and/or apoptotic controls are hallmarks of the 
tumorigenesis process.  p53, also known as tumor protein 53 (TP53), hailed as the 
‘guardian of the genome’ (Lane, 1992), plays important roles in the regulation of cell-
cycle, response to DNA damage and apoptosis (Haupt et al., 2002; Levine, 1997; 
Vousden and Lu, 2002).  p53 is a nuclear phosphoprotein that acts as a transcriptional 
regulator to modulate the expression of numerous downstream target genes both 
positively and negatively (el-Deiry, 1998; Ho and Benchimol, 2003).  It can trans-
activate cell-cycle /apoptotic genes, like MDM2, p21WAF1/CIP1 and BAX, through the 
binding of a consensus sequence, 5’PuPuPuC(A/T)(A/T)GPyPyPy3’ (2 copies 
separated by 0-13 bp), in the target gene (el-Deiry, 1998; Vogelstein et al., 2000).  
p53 is also able to repress the transcription of various genes including genes that 
regulate apoptosis (e.g. survivin) (Hoffman et al., 2002) and the G2/M phase of cell 
cycle (e.g. cyclin B1, cdc2, cdc25c, Mad1) (Chun and Jin, 2003; Innocente et al., 
1999; Taylor et al., 2001; Zhao et al., 2000). The mechanism of repression of genes 
by p53 is less clear.  Transcriptional repression by p53 is thought to occur through a 
few different mechanisms (Ho and Benchimol, 2003).  p53 can directly bind to DNA 
either via the p53 consensus sequences or other novel sequences to repress promoter 
activity.  The binding of p53 to the promoter (e.g. AFP promoter) competitively 
displaces the binding of another stronger transcriptional activator (e.g. HNF-3) to the 
same promoter resulting in repression of the gene (Lee et al., 1999).  In the majority 
of promoters that are repressed by p53, no p53 consensus sequences can be identified.  
Transcriptional repression of these genes may occur either through physical 
interactions with transcriptional activators e.g. HNF4α1, rendering them inactive 
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(Maeda et al., 2002), interfering with the basal transcriptional machinery e.g. the 
TATA-binding protein (Farmer et al., 1996) or through the recruitment of histone 
deacetylases (HDAC) and chromatin remodeling, e.g. MAD1 (Chun and Jin, 2003).    
Dysregulation of p53 is a common phenomenon in most human cancers.  In some 
tumors, p53 is sequestered in the cytoplasm of the cell rendering it unable to function 
as a transcription factor (Moll et al., 1992).  In others, p53 is inactivated by interaction 
with viral proteins or other cellular proteins (Vogelstein et al., 2000).  Deletion or 
mutation of p53 can be observed in approximately half of these tumors.  Majority of 
the naturally-occurring mutations in p53 are in the DNA-binding domain and these 
mutations were found to attenuate p53 ability to trans-activate genes (Vogelstein et 
al., 2000).    
Interestingly in the previous chapter, we found that FAT10 promoter activity 
is 100 times higher in Hep3B (p53-/-) cells compared to HepG2 (p53+/+) cell. Both are 
hepatocellular cells and the major difference between these two cell lines is the status 
of p53. Hence, in this chapter, we explored if p53, in fact, play an important role in 
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3.2  Materials and Methods  
3.2.1 Cell lines and Transfection 
The following cell-lines were used in this study:  KB3-1, a subclone of a HeLa 
cell-line; 293, a human kidney cell-line; HepG2, a hepatocellular carcinoma (HCC) 
cell-line with normal p53 and Hep3B, another HCC cell-line but with its p53 deleted. 
The transfection and β-galactosidase activity assay were performed using the methods 
described in 2.2.1. 
 
3.2.2 Quantitation of FAT10, p53, p21 and MDM2 and β-actin transcript  
The isolation of RNA and synthesizing of cDNA followed the methods 
described in 2.2.2. Real-time polymerase chain reaction (PCR) was performed in a 
Rotor-Gene 2000 Real-Time Thermal Cycler (Corbett Research) using the 
QuantiTectTM SYBR® Green PCR Kit (Qiagen). Amplification reactions comprise 
25ng of cDNA template, 0.25 pmol/ml each of the forward and reverse primers for the 
various genes and 5 ml of 2x PCR Master Mix (Qiagen) in a total volume of 10 ml. 
The primers for the various genes are as follows: p53 (F: 5' 
GACCTATGGAAACTACTTCCT, R: 5' GTACGTGCAAGTCACAGACT); p21 (F: 
5’CCTCAAATCGTCCAGCGACCTT, R:5’CATTGTGGGAGGAGCTGTGAAA); 
MDM2 (F: 5'TGTAAGTGAACATTC AGGTG, R: 5'-
TTCCAATAGTCAGCTAAGGA); primers for FAT10 and β-actin are the same as 
described in 2.2.2. For amplification of the FAT10 transcript, its cDNA was denatured 
at 95oC for 15 min followed by 45 cycles of amplification at 95oC for 30 sec, 64oC for 
30 sec and 72oC for 30 sec, while p53, p21, MDM2 and β-actin amplification 
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involved an initial denaturation at 95 oC for 15 min followed by 40 cycles at 95oC for 
30 sec, 55oC for 30 sec and 72oC for 30 sec. SYBR® Green fluorescence was 
measured after each extension step. Standard curves for FAT10, p53, p21, MDM2 and 
β-actin were generated using serial dilution of plasmids containing the respective 
cDNAs. The linear range for all the respective gene expression was determined to be 
between 103 to 108 copies (r2 for FAT10 is 0.9993; p53 is 0.9992; p21 is 0.9997, 
MDM2 is 0.9994 and β-actin is 0.992 respectively).  FAT10, p53, p21 and MDM2 
expression was normalized against the housekeeping β-actin gene expression.  All 
RT-PCR reactions were performed in triplicate.   
 
3.2.3 Generation of siRNA constructs against p53  
The sense (5’GATCCCGACTCCAGTGGTAATCTACTTCAAGAGAGTAG 
ATTACCACTGGAGTCTTTTTTGGAAA3’) and antisense (5’AGCTTTTCCAA 
AAAAGACTCCAGTGGTAATCTACTCTCTTGAAGTAGATTACCACTGGAGT
CGG3’) (underlined nucleotides denote p53 sequences) (Brummelkamp et al., 2002)  
oligonucleotides of siRNA against p53 were annealed by heating the mixed 
oligonucleotides to 90°C for 3 minutes, then cooled to 37°C and incubated for 1 h.  





































Figure 9. The strategy to construct the SiRNA specific to p53. 
The siRNA p53 sense and antisense oligonucleotides were annealed, and 
cloned to the linearized vector pSilencer 3.0-H1 (Ambion) to get pH1-
Sip53, in which p53 siRNA was driven by RNA Polymerase III promoter 
H1. The construct was confirmed by sequencing in case of point mutation 
during synthesizing.  
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3.2.4 Generation of construct pFATgal-CMVp53  
As showed in Fig 10, first, primer F-p53CMV 
5'CGCTAGGATCTCGAGCTCA (underlined nucleotides denote XhoI cut site)  and 
primer R-p53CMV 5' gagaACCGGTAATTCTCAGTCTGAGTCAGG (underlined 
nucleoti- des denote AgeI cut site) were utilized to amplify p53 gene from pCMV-p53 
construct with XhoI and AgeI double cut sites. The resultant PCR product and vector 
pFAT10-EGFP were double digested with XhoI and AgeI. Finally, the target 
construct pFAT/βgal-CMV/p53 was obtained by insertion of digested PCR product 



























F-p53CMV  5'     CGCTAGGATCTCGAGCTCA
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Figure 10. Strategy for making construct pFAT/β-gal-CMV/p53.   
First, p53 gene was amplified from template pCMV-p53 with XhoI and 
AgeI double cut sites. Then the obtained PCR product and vector 
pFAT10-EGFP were double digested with XhoI and AgeI. Finally, the 
target construct pFAT/βgal-CMV/p53 was obtained by insertion of 
digested PCR product into the digested vector. 
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3.2.5  Determination of the binding of p53 to FAT10 promoter region using 
DNA and chromatin immuno-precipitation (DIP and ChIP) 
To delineate the region of the FAT10 promoter that p53 binds to, FATprom or 
FATpromp53mut constructs were co-transfected with either pCMV-p53 or vector 
control into Hep3B cells using calcium phosphate co-precipitation.  Cells containing 
the various constructs were harvested 48h after transfection and DNA 
immunoprecipitation was performed using the ChIP (chromatin immunoprecipitation) 
assay kit (Upstate Cell Signaling Solutions).  Proteins and DNA in the transfected 
cells were crosslinked with 1% formaldehyde, the DNA-protein complex sheared 
through sonication and immunoprecipitated with either 1 µg of anti-p53 (Santa Cruz 
Biotechnology) or control anti-β-actin antibody. After reversing the crosslinked DNA-
protein complex, DNA was recovered from the immunoprecipitate through phenol-
chloroform extraction and ethanol precipitation.  Real-time PCR was then performed 
to quantitate the amount of specific FAT10 promoter region that binds p53.  The input 
total lysate that has been crosslinked (but not immunoprecipitated), reverse 
crosslinked and DNA extracted was utilized to normalize for differences in the 
amount of DNA present in the different samples.  Real-time polymerase chain 
reaction (PCR) was performed in a Rotor-Gene 2000 Real-Time Thermal Cycler 
(Corbett Research) using the QuantiTectTM SYBR® Green PCR Kit (Qiagen).  
Amplification reaction comprises 1µl template, 0.25 pmol/ml of each of the primers 
(forward: 5'ATGGACACATAACCCAGGATG and reverse: 
5'TTCTCGTTCCTTGAATTCCC). Primers for this real-time PCR assay were 
designed approximately 100bp upstream and downstream of the 5’ half consensus 
sequence of p53 binding site. Conditions for the amplification are denaturation at 
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95oC for 15 min followed by 25 cycles at 95oC for 30 sec, 55oC for 30 sec and 72oC 
for 30 sec. Standard curve was generated using plasmids containing the fragment of 
DNA. The linear range for this amplification was determined to be between 102 to 108 
copies (r2=0.998). 
To demonstrate that the p53 binds to endogenous FAT10 promoter in vivo, 
Hep3B cells were transfected with either the pCMV-p53 construct or the vector 
construct and chromatin immunoprecipitation assay was performed using the ChIP 
assay kit (Upstate Cell Signaling Solutions) as described above except that 33 instead 
of 25 cycles of amplification was performed.  To show that the promoter region and 
not other regions of FAT10 is specifically amplified, PCR was also performed on the 
input lysate of immunoprecipitated chromatin using primers (forward:  
5’CTGTCTTGTGGCTTTCACTTC and reverse: 5’TGCCTCTTTGCCTCATCACC) 
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3.3  Results  
3.3.1  p53 negatively regulates FAT10 promoter activity. 
To test the hypothesis that p53 represses FAT10 promoter activity, we 
introduced wild-type (wt) p53 into p53-/- Hep3B cells. As shown in Fig 11A, FAT10 
promoter activity is significantly inhibited in cells transfected with FATprom or FAT 
(-1176/+209) or FAT (-1997/+209) and wt p53 compared to cells transfected with 
FATprom or FAT(-1176/+209) or FAT(-1997/+209) and vector control. Furthermore, 
p53 repressed FAT10 promoter activity in a dose-dependent manner (Fig. 11B). 
Similarly, endogenous FAT10 transcript expression was also found to be significantly 
repressed when wt p53 rather than vector control was introduced into these Hep3B 
cells (Fig. 12). 
We also demonstrate that this repression can be reversed by the addition of 
siRNA against p53.  Constructs pH1-sip53, whereby the siRNA against p53 is driven 
by the H1 polymerase III promoter (Fig. 13A, upper panel) and pFATgal-CMVp53, in 
which the FAT10 promoter drives the β-galactosidase reporter gene and the CMV 
promoter drives the p53 gene (Fig. 13A, bottom), were utilized in this experiment.  
Hep3B cells containing pFATgal-CMVp53 and pH1-sip53 constructs showed 
significantly enhanced promoter activity compared to cells containing pFATgal-
CMVp53 and pH1-control, a control siRNA against a sequence with limited 
homology to any known sequences in human, mouse and rat genome (Ambion) 























































































































































































































































































































Figure 11. p53 repression of FAT10 promoter activity. (A) Hep3B 
cells were co-transfected by FAT10 promoter constructs with either 
vector control (control without p53 gene insertion) or pCMV-p53 
construct.  Normalized promoter activity from four separate experiments 
(mean + SE) is presented.  * and ** denotes significant difference 
(P<0.05 and P<0.01 respectively) between the various FAT10 promoter 
constructs + control and the various FAT10 promoter constructs + 
pCMV-p53 respectively. The lower panel showed western Blot analyses. 
(B) The repression of p53 on FAT10 promoter activity shows dose 
dependence. FAT (-1997/+209) was used in this experiment and 
cotransfected with 2µg, 6µg or 8µg of pCMV-p53, or with same amount 
of control vector. ** denotes significant difference (P<0.01) between 
FAT(-1997/+209) + control and FAT(-1997/+209) + pCMV-p53. The 
results of transient transfection are presented as β-gal enzymatic activity 
(normalized against protein) as the mean ±SE of four individual 
experiments 
  










































































































Figure 12. Repression of FAT10 transcription level in Hep3B cells by 
p53.  
pCMV-p53 was used to transfect into Hep3B cells. The control (vector 
control without p53 gene insertion) is utilized to complement the DNA 
amount of transient transfection. Real-time PCR was used to study the 
transcription level of FAT10 gene in Hep3B cells. (A) Diagram of Real-
time PCR raw data shows that there is different Ct between control group 
and pCMV-p53 group. (B) Comparing with the control samples, 
transcription level of FAT10 gene is significantly lower (p<0.05) in 
Hep3B cells transfected with p53 construct. The results of Real-time PCR 
are presented as mRNA copy number (normalized against β-actin mRNA 
copy number) in Hep3B cell as the mean ±SE of three individual 
experiments. 
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Figure 13. Release the repression of p53 to FAT10 promoter by pH1-
Sip53 in Hep3B cells. 
(A) Constructs utilized in this experiment. The siRNA construct pH1-Sip53 
(including pH1-control) was constructed as in Figure 5. The pH1-Sip53 
construct comprises sequences of siRNA against p53 upstream the H1 
RNA promoter. A control siRNA contruct (pH1-control) (not shown) 
provided by the vendor (Ambion) contains sequences of siRNA against 
sequences with limited homology to any known sequences in human, 
mouse and rat genome cloned into a similar vector as pH1-Sip53. 
pFATgal-CMVp53 construct comprises FATprom upstream of the β-gal 
reporter and the p53 gene downstream of the constitutive CMV promoter 
(Fig. 10). (B) For the upper panel, comparing with the control samples, the 
activity of FAT10 promoter in experiment sample was much higher due to 
the cotransfection of pH1-Sip53 whose transcription had silenced the 
expression of p53 gene in the cotransfected cells (p<0.01). The result of 
transient transfection is presented as β-gal enzymatic activity (normalized 
against protein concentration) in Hep3B cell as the mean ±SE of eight 
individual experiments. For the lower panel, result of Western-blot showed 
that there was a strong band of p53 in first lane due to the expression of 
p53 driven by CMV promoter. In second lane, however, the p53 band was 
extenuated significantly due to the transcription of specific SiRNA that can 
degrade p53 mRNA. The western-blot result of β-actin is used as control. 
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 Notably, when endogenous p53 expression in KB3-1 and 293 cells was 
inhibited using siRNA against p53, significantly enhanced FAT10 promoter activity 
(P<0.01) was observed (Fig. 14).  Likewise, when siRNA against p53 was transfected 
into 293 cells, p53 expression was significantly inhibited (Fig. 15B) resulting in the 
inhibition of expression of known p53 regulated target genes including p21 and 
MDM2 (Vousden and Lu, 2002) (Fig. 15C and 15D) but not genes that are not 
regulated by p53 e.g. β-actin. Significantly, when endogenous p53 expression in 293 
cells was inhibited by siRNA against p53, endogenous FAT10 expression was 
increased significantly (Fig. 15A).   
These series of experiments unequivocally demonstrate the role of p53 in 












































































































































































































































































Figure 14. FAT10 promoter activity is enhanced by the addition of 
siRNA against p53 in p53+/+ KB3-1 cells and 293 cells.  
KB3-1 cells and 293 cells were initially either untransfected or transfected 
with pH1-Sip53 or pH1-control (control).  After 24h, these cells were then 
transfected with FATprom (see Fig. 4) and FAT10 promoter activity 
assayed 48 h later. A and B shows normalized FAT10 promoter activity 
from 11 (KB3-1) or 8 (293) separate experiments (mean + SE) 
respectively.  ** denotes significant difference at P<0.01 between cells 
transfected with pH1-Sip53+FATprom and pH1-control+FATprom or 
FATprom alone. A’ and B’ show Western blot of these two types of cells 
hybridized either with anti-p53 or anti-β-actin antibodies. 
  


















































































































































































































































































































































































































































































































































































































































































































































































Figure 15. Endogenous FAT10 transcriptional level is also related to 
endogenous p53, along with other p53 regulated genes.   
FAT10 expression is enhanced by the addition of siRNA against p53 in 
p53+/+ 293 cells. 293 cells are transfected with either pH1-control or pH1-
Sip53, and FAT10, p53, p21 and MDM2 expression was quantitated using 
either real-time RT–PCR or densitometry. The figure shows relative 
FAT10 transcript levels (normalized against β-actin) from three different 
experiments (mean7s.e.). ** denotes significant difference at P<0.01 
between cells transfected with control siRNA and siRNA against p53. 
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3.3.2  p53 binds to the 5’ half consensus sequence of p53 binding site of the 
FAT10 promoter and plays a role in the responsiveness of FAT10 promoter to 
p53 
In silico analyses of the region of the FAT10 promoter that conferred highest 
activity revealed a putative 5’ half consensus sequence of p53 binding site residing 
between -240 bp to -220 bp upstream the transcription start site (Fig. 5). To determine 
if this region confers responsiveness of the promoter to p53, we mutated this putative 
p53 binding half site (Fig. 16A) and compared their activity in the presence or 
absence of p53. As shown in Fig. 16B, its responsiveness to p53 was abrogated by 
this mutation as evident by the similar promoter activity in the presence or absence of 
p53 in cells transfected with pFATpromp53mut suggesting that the p53 binding half 
site plays an important role in determining the responsiveness of the FAT10 promoter 
to p53. Curiously, this mutation resulted in a significant attenuation of FAT10 
promoter activity as evident by the significantly lower reporter activity when 
pFATpromp53mut rather than pFATprom is transfected into Hep3B cells (Fig. 16B). 
Similar reduction in promoter activity was also observed in p53+/+ cells (HepG2 and 
KB3-1) containing the pFATpromp53mut compared to those containing the 
pFATprom construct (Fig. 16C) revealing that this inhibition of promoter activity is 
independent of the p53 status. This is probably due to creation of additional 
transcriptional repressor binding site or the abolishment of a transcription activator-
binding site when that site was mutated.  In silico examination using the MatInspector 
program (http://www.genomatix.de/) did not reveal the abolishment or creation of 
known transcription activator/repressor sites.  Nonetheless, it does not rule out that 
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novel transcription factor binding sites may be created or abolished or that there are 




































































Figure 16. Delineation of regions in FAT10 promoter that is 
responsible for the responsiveness of the promoter to p53.  
 (A) Primers and strategy for generating the p53 binding site mutant.  The 
p53 binding half site mutant was generated via a 2-step polymerase chain 
reaction (PCR). In the first step, 2 separate PCR products were generated 
using the following pairs of primers respectively:  (1) FAT (-975)-F and 
Muta-p53-R and (2) Muta-p53-F and FAT (+209)-R.  The purified and 
amplified PCR products were then combined and amplified using primers 
FAT (-975)-F and FAT (+209)-R to obtain a whole length fragment.  (B) 
Normalized promoter activity in Hep3B cells from four separate 
experiments (mean + SE) is presented on the top panel. ** denotes 
significant difference (P<0.01) between the various FAT10 promoter 
constructs + control and the various FAT10 promoter constructs + pCMV-
p53.  Western Blot analyses of these cells using anti-p53 and anti-β-actin 
(Actin) antibodies are presented in the middle 2 panels. Pictorial 
representation of the different FAT10 promoter constructs is shown in the 
lowest panel. (C) Normalized promoter activity in KB3-1 cells and HepG2 
cells from four separate experiments (mean + SE) is presented. ** denotes 
significant difference (P<0.01) between the wild type FAT10 promoter 
constructs and the FAT10 promoter mutant construct in KB3-1 cells and 
HepG2 respectively. 
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To determine if p53 binds to this consensus site to repress FAT10 expression 
in cells, in vivo DNA immunoprecipitation assay was performed.  As shown in Fig 
17A, when FATprom or vector-control constructs were transfected into Hep3B cells 
and the cells were immunoprecipitated with anti-β-actin or anti-p53 antibodies, 
respectively, only basal amplification of the FAT10 promoter region encompassing 
the putative p53 binding half-site was observed.  However, significant enrichment 
(P<0.01) of this region was observed via real-time PCR when FATprom-transfected 
cells were immunoprecipitated with anti-p53 antibodies. Notably, when the p53 
binding half site was mutated, the affinity of binding of p53 to that site decreased 
significantly compared to the wild-type promoter (P<0.01) (Fig. 17B). To evaluate if 
p53 binds the chromatin region around the p53 consensus half-site of the endogenous 
FAT10 promoter in vivo, pCMV-p53 or vector control was transfected into Hep3B 
cells and chromatin immunoprecipitation (ChIP) assays were performed with anti-p53 
or anti-β-actin antibodies. As evident in Fig 18, amplification of the chromatin region 
encompassing the p53 consensus half-site was only evident in cells transfected with 
pCMV-p53 and immunoprecipitated with anti-p53 antibodies.  No amplification was 
observed in the control lanes.  
These results suggest that p53 directly binds to the FAT10 promoter primarily 
at the p53 binding half site region located at -240 bp to -220 bp upstream of the TSS 

































Figure 17. FAT10 promoter region emcompassing the p53 binding 
half site binds p53 in vivo.   
FATprom or FATpromp53mut constructs were co-transfected with either 
pCMV-p53 or vector control into Hep3B cells. Immuno-precipitation was 
performed with anti-p53 or control β-actin antibodies.  (A) Agarose gel 
representation of the PCR product after 25 cycles using primers 100 bp 
upstream and downstream the p53 binding half site of the FAT10 
promoter (B) Real-time PCR quantitation of the PCR products which was 
normalized against input chromatin to correct for differences in the 
amount of DNA present in the different samples.  “Precipitated” denotes 
DNA that has been crosslinked, immunoprecipitated with either anti-p53 
or anti-actin antibodies, reverse crosslinked and DNA extracted; “Input” 
denotes total chromatin that has been crosslinked (but not 
immunoprecipitated), reverse crosslinked and DNA extracted.  ** denotes 
significant difference (P<0.01) between amount of FATprom 
immunoprecipitated by p53 Ab and FATprom immunoprecipitated by β-
actin Ab or FAT-p53mut or vector control immunoprecipitated by p53 Ab.   
 
  















































































































































































































































































































































































Figure 18. p53 binding the chromatin of the FAT10 promoter region 
emcompassing the p53 binding half site.  
pCMV-p53 or vector control were transfected into Hep3B cells. ChIP 
assay was performed with anti-p53 or control β-actin antibodies. Agarose 
gel represents the PCR product after 33 cycles (for input DNA, 29 cycles) 
using primers 100 bp upstream and downstream of the p53 binding half 
site of the FAT10 promoter or primers within exon 2 of the FAT10 gene. 
“Precipitated” denotes chromatin that has been crosslinked, 
immunoprecipitated with either anti-p53 or anti-actin antibodies, reverse 
crosslinked and DNA extracted; “Input DNA” denotes total chromatin that 
has been crosslinked (but not immunoprecipitated), reverse crosslinked 
and DNA extracted 
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3.4  Discussion 
FAT10 is interesting to cancer biologists because of its potential role in cell-
cycle/apoptosis regulation and tumorigenesis. FAT10 belongs to the UBL family 
whose members have been implicated to play important roles in cell-cycle 
regulation/apoptosis (Jentsch and Pyrowolakis, 2000; Jesenberger and Jentsch, 2002).  
Furthermore, it comprises 2 ubiquitin-like domains fused in tandem.  The ubiquitin 
pathway is an important player in cell-cycle regulation (Pagano, 1997; Pines, 1994).  
Additionally, FAT10 was found to interact with MAD2, a mitotic spindle checkpoint 
protein (Liu et al., 1999) which has been shown to be important for maintaining 
genome stability (Michel et al., 2001). Dysregulation of MAD2 has also been 
implicated in tumorigenesis (Li et al., 2003; Michel et al., 2001; Wang et al., 2002).  
Notably, FAT10 expression was found to be up-regulated in hepatocellular carcinoma 
and other gastrointestinal and gynecological cancers (Lee et al., 2003) and the 
overexpression of FAT10 results in dysregulated Mitosis and Chromosome 
Instability(Ren et al., 2006). 
 Notably, we demonstrate through a series of experiments that FAT10 gene 
expression and promoter activity is negatively regulated by p53 (Figs. 11-16) 
implicating FAT10 in the pathway of p53 as a downstream gene. The introduction of 
wild-type p53 into p53-/- Hep3B cell line inhibited FAT10 transcript expression and 
promoter activity (Fig. 11, 12) which can be alleviated by the addition of siRNA 
against p53 (Fig. 13).  Furthermore, siRNA against p53 enhanced FAT10 promoter 
activity in the p53+/+ KB3-1 and 293 cell-lines (Fig. 14) as well as FAT10 transcript 
expression in 293 cell line (Fig. 15). 
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 Downstream target genes that are negatively regulated by p53 include genes 
regulating apoptosis (Hoffman et al., 2002) and the G2/M of the cell-cycle (Chun and 
Jin, 2003; Innocente et al., 1999; Taylor and Stark, 2001; Zhao et al., 2000).  One of 
the G2/M genes that are down-regulated by p53 is MAD1 (Chun and Jin, 2003).  Both 
MAD1 (Luo et al., 2002) and FAT10 (Liu et al., 1999) are capable of interacting with 
MAD2, the spindle checkpoint protein whose dysregulation can lead to genomic 
instability and tumorigenesis (Hernando et al., 2004; Michel et al., 2001). 
 Transcription repression of downstream target genes by p53 is thought to 
occur via one of a few mechanisms (Ho and Benchimol, 2003). p53 may directly bind 
to p53 consensus site to repress promoter activity or it may act through the 
interference of the basal transcriptional machinery via the binding of p53 to the 
TATA binding protein (Farmer et al., 1996) or the binding of other transcriptional 
factors. Other mechanisms of repression of the FAT10 promoter activity by p53 
include the recruitment of HDAC1-mSin3a repression complex to the promoter which 
was observed in the negative regulation of MAD1 by p53 (Chun and Jin, 2003).  
Using in silico strategies, we identified a putative 5’ half consensus sequence of p53 
binding site (p53 binding half site) residing between -240 bp to -220 bp of the FAT10 
promoter (Fig. 5). We demonstrated that when this site was mutated, the FAT10 
promoter responsiveness to p53 was abrogated (Fig. 16). Importantly, we demonstrate 
through DNA immunoprecipitation analyses that p53 binds to the FAT10 promoter in 
vivo via this consensus site as the binding was significantly reduced (P<0.01) when 
this consensus site was mutated (Fig. 17). Through ChIP analyses we further 
demonstrate that p53 binds to this region of the endogenous FAT10 promoter (Fig. 
18). 
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 In summary, p53 is likely an upstream regulator of FAT10 and may link 
FAT10 in the tumorigenesis process. The biological significance of p53-mediated 
repression of FAT10 gene in tumorigenesis warrants further investigation. As FAT10 
was found to interact with MAD2, a mitotic checkpoint protein (Liu et al., 1999), an 
attractive hypothesis would be that the repression of FAT10 expression by p53 may 
facilitate the interaction of MAD2 with cdc20 to induce mitotic arrest. During 
tumorigenesis, p53 may not function appropriately, leading to the enhancement of 
FAT10 gene expression which is observed in several different cancers (Lee et al., 
2003). More FAT10 will then interact with MAD2 which may result in the 
deregulation of mitosis, leading to genome instability and tumorigenesis.   It would be 
interesting to explore the relationship of FAT10 and p53 expression in HCC patients. 
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4.1  Background 
FAT10 expression was reported to be up-regulated in the tumors of 
hepatocellular carcinoma (HCC) as well as other gastrointestinal and gynecological 
cancers (Lee et al., 2003). This aberrant over-expression of FAT10 gene in tumor 
tissues may be a result of mutations within the FAT10 promoter or aberrant 
methylation at the FAT10 promoter.   
Mutations within the promoter of genes have been shown to result in the 
overexpression of genes in cancer cells. For example, a mutation of the CDE/CHR 
repressor elements at the survivin promoter was found to result in the overexpression 
of survivin in some cancer cells (Xu et al., 2004). Similarly mutations at the hMSH2 
gene in suspected cases of HNPCC and sporadic early onset colorectal cancer patients 
were found to affect its promoter activity as well as the transcription start site and the 
transcriptional factor binding site, resulting in a novel DNA-protein complex (Shin et 
al., 2002).   
Aberrant methylation at promoter of genes may also account abberant 
expression of the genes involved in the tumorigenesis process. DNA methylation is a 
post-replicative modification in which a DNA residue acquires a covalently bond 
methyl group. DNA methylation in vertebrates typically occurs at CG dinucleotides 
(cytosine locates 5’ to guanine) whereby one of hydrogen atom (H) of cytosine is 
replaced with a methyl group. This methylation results in the conversion of the 
cytosine to 5-methylcytosine (Laird and Jaenisch, 1996). CG sites are uncommon in 
vertebrate genome but are often found at higher density near vertebrate gene promoter 
where they are collectively referred to as CpG island. The methylation status of CG 
sites may influence gene regulation in the following ways. Hypermethylation of CG 
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islands in the promoters of cancer-related genes is often associated with 
transcriptional inactivation (Baylin et al., 1998; Jones and Laird, 1999). Numerous 
publications demonstrated the involvement of DNA methylation in the silencing of 
tumor-suppressor genes (Costello and Plass, 2001; Esteller et al., 2001; Jones and 
Baylin, 2002). Nontheless, numerous other studies have also documented reduced 
methylation of proto-oncogene promoter regions, suggesting a role for DNA 
hypomethylation in the activation of proto-oncogenes (Ray et al., 1994; Vorce and 
Goodman, 1989). 
The methylation status of the CG dinucleotides may regulate gene expression 
in the following ways. De novo methylation or demethylation in 5’ promoter region of 
related genes was found to alter the accessibility of transcriptional factors to that 
promoter, thus changing the expression level of the gene (Davey et al., 1997; Patel et 
al., 1997). Alternatively, repression of some genes by methylation may not involve 
the direct methylation of the transcriptional binding site but depends on the chromatin 
condensation status that is influenced indirectly by the distant methylated sites (Pieper 
et al., 1996). It is also possible for methyl-binding protein MeCP2 that binds to 
methylated CG sites in a complex with histone acetylase to induce local histone 
deacetylation resulting in a repressive chromatin configuration that is inaccessible to 
the transcription complex (Jones et al., 1998; Nan et al., 1997).  
Since FAT10 is aberrantly over-expressed in the tumors of HCC and other 
cancer patients, we would like to evaluate if the dysregulation of FAT10 expression is 
due to mutations at the FAT10 promoter region or an aberrant methylation at the 
FAT10 promoter.  
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4.2  Materials and Methods 
4.2.1  Patient samples 
All human samples were obtained in accordance to the guidelines and with 
approval from the Institutional Review Board (IRB) of the National Cancer Centre of 
Singapore. All the samples were stored in liquid nitrogen. 
 
4.2.2  Isolation of genomic DNA and RNA from tissue samples  
Genomic DNA was isolated directly from liver tissue using the DNeasyTM 
Tissue Kit (QIAGEN). The experimental steps followed the protocol provided by the 
manufacturer. The DNA was quantitated using a spectrometer (Spectromax plus 384, 
Molecular devices) at 260nm. The absorbance under wavelength 280 nm was also 
measured and the DNA quality was evaluated by calculating the ratio of A260/A280. 
Isolation of total RNA from tissue samples followed the method described in 
section 2.2.2. FAT10 transcript levels in human liver samples were determined by real 
time PCR following the method described in section 3.2.2. 
 
4.2.3  Identification of Mutations/Polymorphisms through DNA sequencing  
The region 1379bp (-1066 upstream and +313 downstream of the 
transcriptional start site), which includes the promoter region with the highest activity, 
exon I and part of intron, was sequenced to screen for mutations or polymorphsims in 
tumor tissue and adjacent non-tumorous liver tissues from 37 HCC patients and 39 
DNA samples from healthy people. The primers designed to amplify this region from 
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genomic DNA were F-5'ACTAATAGAGGTGGTTCCTTA (forward primer) and R-
5' CTCTCCCCAACTCTTGAAAGT (reverse primer). The PCR reaction condition 
was as follows: 95oC 15mins, then 30 cycles of 94oC for 30 secs, followed by 55oC 
for 45sec and a extension at 72oC for 1mins, followed by a final extension at 72oC for 
5 mins. Sequencing reaction was performed as described in 2.2.3. Sequencing results 
were analyzed with ABI PRI 3100 Genetic Analyzer (Applied Biosystems). 
Haplotype frequencies was estimated using the program Arlequin 
(http://lgb.unige.ch/arlequin/) which is based on the Expectation-Maximization (EM) 
algorithm (Excoffier and Slatkin, 1995). The significance of differences in haplotype 
frequencies between populations was compared using the Fisher’s Exact Test.  
To evaluate the functionality of mutation/SNPs at the FAT10 promoter region, 
site directed mutagenesis was employed to mutate the putative specific sites according 
to the haplotypes inferred. The PCR fragments with the mutated site to represent the 
different haplotypes were inserted into a linearized vector pEGFP (Fig 2). FAT10 
promoter activity was analyzed as described in section 2.2.1. All constructs were 
verified by sequencing to exclude PCR-induced nucleotide mis-incorporations prior to 
use. 
 
4.2.4  Determination of the Methylation Status at the FAT10 promoter using 
Methylation-Specific Sequencing  
To determine the methylation status of FAT10 promoter in HCC patients, 
genomic DNA was treated with sodium bisulfite as described (Olek et al., 1996). All 
cytosine (C) in the genomic DNA should be converted to thymidine (T) by bisulphite 
treatment except for cytosines that are methylated. Primers were then designed 
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according to the template whose C was converted to T. A half-nest PCR was utilized 
for this experiment because of the low amount of template. Primer F-sense-A 
5’TTATTTTTTGTGTTTGATAGTATGT with reverse primer FAT (+26)-R 5' 
TCACATACTTCTCTCCTCAA were used in the initial PCR reaction which 
comprises 95oC for 15mins, followed by 25 cycles of 94oC for 30 secs, 55oC for 45sec 
and 72oC for 50 secs, then a final extension at 72oC for 5 mins. Thereafter, 5µl of the 
initial PCR product was used as template to perform second round PCR with forward 
primer F-sense-A 5’TTATTTTTTGTGTTTGATAGTATGT and reverse primer R-
antisense-A 5’ ATCTTTATCTATTAAAACCACCTAA in a 50µl reaction volume 
with the following the PCR condition: 95oC 15mins, followed by 30 cycles of 94oC 
for 30 secs, 53oC for 45 secs and 72oC for 45 secs, then a final extension at 72oC for 5 
mins. The PCR product was sequenced as described in section 2.2.3.   Kappa statistics 
(http://www.dmi.columbia.edu/homepages/chuangj/kappa/) was employed to 
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4.3  Results 
4.3.1  The expression levels of FAT10 in tumour tissue are much higher than 
adjacent non-tumorous liver tissues 
To confirm the previous observation that FAT10 expression is up-regulated in 
the HCC tumour compared to the adjacent non-tumorous liver tissues, 31-paired 
samples (tumour and adjacent non-tumorous) were used in this study. Real-time PCR 
was employed in this experiment to examine FAT10 RNA levels in HCC tumour and 
adjacent normal liver tissues. As shown in Fig 19, the mean of the relative transcript 
levels in the tumor tissues of HCC patients is much higher than that in adjacent non-
tumorous tissue (P<0.01). Approximately 90% of samples showed a higher FAT10 
expression in tumour tissue compared to adjacent non-tumorous tissues (data not 
shown). Hence, this result confirms our previous findings that the FAT10 gene is 
upregulated in HCC tumour tissue in comparison to adjacent non-tumorous tissue 














































































































Figure 19. Comparison of FAT10 transcript level in tumor tissues 
and adjacent non-tumorous tissues.  
The absolute transcript of FAT10 from tumor tissues or non-tumorous 
tissues was deduced from the Ct (threshold cycle number from Real-time 
PCR) and then normalized against the absolute transcript of β-actin 
respectively. Y axis show the mean of the relative FAT10 transcription 
level in 31 paired HCC samples. The real-time RT-PCR was repeated 
three times. ** denotes significant difference (P<0.01) between the 
transcript level of FAT10 in tumor tissues and adjacent non-tumorous 
tissues. 
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4.3.2  Only polymorphisms, but not mutations were identified in the ~1.3kb 
region of FAT10 promoter  
To evaluate if mutations/polymorphisms at the FAT10 promoter can account 
for the aberrant over-expression of FAT10 in the tumors of HCC patients, we 
sequenced approximately 1.3 kb of the FAT10 promoter in the tumor and paired non-
tumorous tissues from 37 Chinese HCC patients and 39 samples from normal healthy 
Chinese individuals. No difference in the sequence of the 1.3kb of the FAT10 
promoter examined was observed between the tumor tissues and adjacent non-
tumorous tissues suggesting that within the 1.3kb region, there are no mutations that 
can account for the difference in expression between the tumor and adjacent non-
tumorous tissues.   
Nonetheless, we identified 6 Single Nucleotide Polymorphisms (SNPs) in this 
region. Four of these SNPs have been previously identified (Fig. 20 and Table 2). 
Two of these SNPs are located in exon I while the other 4 SNPs were found upstream 
of exon I (Fig. 20A and Table 2). Most of the SNPs, with the exception of SNP5 (e1 –
143 A>G) in the normal samples, showed no significant deviation from the Hardy 
Weinberg Equilibrium (Table 2). The significant deviation from Hardy Weinberg 
Equilibrium of SNP5 (e1 –143 A>G) may be due to the small number of the samples 
examined. Three SNPs, SNP6 (e1 –121 A>G), SNP5 (e1 –143 A>G) and SNP3 
(5’UR –616 T>C), have high major allele frequency of greater than 10%, while the 
others including the two novel SNPs (SNP4 5’UR -169 C>T and SNP2 5’UR –876 
G>A) were of low allele frequency (<5%). The three major SNPs and low frequency 
SNP4 (5’UR-169C>T) were observed in both the DNA of HCC samples and normal 
samples (Table 2). However, the other two low frequency SNPs, SNP1 (5’UR –914 
  





















Figure 20. SNPs in FAT10 promoter.   
(A) The location of SNPs in FAT10 promoter. There are six SNPs 
identified in ours and previous studies in FAT10 promoter, three 
common SNPs which are SNP3 (5’UR -616 T>C), SNP5 (e1 -143 A>G) 
and SNP6 (e1 -121 A>G) and three low frequency SNPs which are 
SNP1 (5’UR -914 G>C), SNP2 (5’UR –876 G>A) and SNP4 (5’UR –
169 C>T). Both SNP2 and SNP4 are two new SNPs (not reported 
before). (B) SNPs haplotype frequency of FAT10 promoter in HCC 
patient samples (tumor tissue and adjacent non-tumor tissue) and normal 
samples from healthy population. Haplotype frequencies were derived 
from genotype data using Arlequin. Tumor tissue and adjacent non-
tumor tissue show exactly the same SNPs and haplotype profiles. 
Haplotype 5, 6, 7 specifically belong to HCC patient group, while 
haplotype 8 was only fond in normal population. No significant 
difference was observed in the haplotype distribution of HCC samples 
and normal samples (the Fisher’s exact Test, p>0.05)  
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G>C) and SNP2 (5’UR –876 G>A) in the FAT10 promoter were observed only in the 
HCC patient samples (Table 2).  
From the genotype data of these six SNPs, a total of seven haplotypes were 
inferred from HCC patients using an expectation maximisation (EM) algorithm in the 
ArlequinTM software program (Fig. 20B). As there was no difference in the sequence 
between tumor and adjacent non-tumorous tissue, no difference was observed in the 
haplotype distribution of tumor versus adjacent normal tissues from HCC patients.   
Although no significant difference in the haplotype distribution was observed 
between HCC patients and normal individuals (Fisher’s Exact Test, P>0.05) (Fig. 
20B), there were three low frequency haplotypes that were only found in HCC 
patients (CGTCAG, GATCAG and GGTTGG) and one (GGCTAA) that is only 
observed in normal individuals (Fig. 20B). More samples may need to be examined 
before any conclusions can be drawn.  
An in silico strategy using the web-based program, MatInspector, was 
employed to evaluate whether the SNPs at the FAT10 promoter can potentially affect 
transcription factor binding. As shown in Table 2, the putative transcription factor 
binding sites were abolished in 2 SNPs identified in the 5’ untranslated region of 
FAT10 gene. The major G allele of SNP2 (5'UR-876G>A) was predicted to be bound 
by GATA-binding factor 2 and hepatic nuclear factor 1, whereas the alternative minor 
A allele was predicted not to bind any factor. Similarly, the major T allele of SNP3 
(5'UR -616T>C) predicts a myocyte enhancer factor-binding site, whereas the 
alternative minor C allele does not. The creation of putative binding sites was 
predicted for two SNPs (SNPs 1 and 6) (Table 2).  Finally, for the last 2 SNPs (SNPs 
4 and 5), the putative binding sites predicted for the major allele not longer exist when  
  




















































































































































































Figure 21. FAT10 Promoter activity with different haplotype 
structures.  
Promoter activity of FAT10 promoter with different haplotype structures 
were determined as β-gal activity (normalized against EGFP). 
Experiment was carried out in hep3B cells and performed in four 
independent occasions. The order of SNPs in a haplotype structure is 
from 5’ to 3’ (Figure20). The hapolotypes with high frequency were 
boxed. ** denotes significant difference (P<0.01) between the various 
FAT10 promoter haplotype structures and wild type haplotype structure 
GGTCAA.  
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the minor allele was substituted but new binding sites were predicted for the minor 
allele of the SNPs (Table 2). Hence, polymorphisms at the promoter region of the 
FAT10 gene may potentially alter the binding of transcription factors. 
We proceeded to experimentally evaluate whether SNPs in FAT10 promoter 
may alter FAT10 promoter activity. Inferred haplotype of SNPs (Fig.20B) at the 
FAT10 promoter were recapitulated using PCR site-directed mutagenesis and cloned 
into the β-galactosidase reporter construct (Fig. 2). The activity of FAT10 promoter 
with the different haplotypes was then evaluated in Hep3B cells by analysing β-gal 
reporter gene activity after transfection. As shown in Fig 21, there is significant 
difference (P<0.01) between the various mutated haplotypes and wild type haplotype 
GGTCAA.  Interestingly, haplotypes (GGTCAG, GGTCGG and GATCAG) result in 
significantly higher FAT10 promoter activity while haplotypes (GGCCAA, 
CGTCAG, GGTTGG and GGCTAA) mediate significantly lower FAT10 promoter 
activity. From these data, it seems that changing SNPs 6, 5 or 2 generally results in 
significantly higher FAT10 promoter activity.  The only exception is when SNP1 and 
SNP6 are changed simultaneously as observed in haplotype CGTCAG. This 
haplotype resulted in a significantly lower FAT10 promoter activity.  Changing SNPs 
3 and 4 was observed to result in significantly lower FAT10 promoter activity. These 
results suggest that polymorphisms within the FAT10 promoter may alter FAT10 
promoter activity and expression.   
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4.3.3  Differential Methylation at the FAT10 promoter was observed between 
tumour and adjacent normal liver tissues of HCC patients 
A total of seven CG dinucleotides (CG-1 to CG-7) reside in the region from –
975 to +209 bp of the FAT10 promoter which showed the highest promoter activity 
(Fig. 22). All these CG dinucleotides reside upstream of the TSS (transcription start 
site). In order to evaluate the effect of DNA methylation on FAT10 expression, 
methylation-specific sequencing was utilized to evaluate the methylation status of 
different CG dinucleotides in the FAT10 promoter region. As shown in Fig 23A (a), 
the unmethylated cytosine is converted to U by treatment with bisulfite solution. 
However, if C (Cytosine) is methylated, then it cannot be converted to U with 
bisulfite treatment (Fig. 23A(b)). In Fig 23B, the sequencing results show that there 
are three kinds of methylation of CG sites in FAT10 promoter region. CG sites can be 
fully methylated (1), half methylated (2) and unmethylated (3). 
 Tumor and adjacent non-tumorous liver tissue samples from 11 HCC patients 
were used in this study. As evident in Table 3, except for patients 6, 10 and 11, the 
methylation status of the other 8 HCC patients generally correlated with their 
transcript expression levels. Less methylation in the tumor tissues is correlated with 
higher expression of FAT10 in the tumor tissues (Patients 2, 3, 4, 7, 8 and 9).  
Conversely, as evident in patient 1, higher methylation in HCC tumor is correlated 
with lower FAT10 transcript expression. Likewise, no differential methylation was 
observed in patient 5 in which the FAT10 was found not to be differentially expressed 
in the tumors compared to the adjacent normal tissues. Nonetheless, utilizing kappa 
statistics (http://www.dmi.columbia.edu/homepages/chuangj/kappa/), the methylation 
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status was found to inversely correlate significantly with FAT10 expression (Kappa 
value=0.468). 
Hence, it is likely that methylation may play an important role in regulation of 
FAT10 expression level. 
  





































































































































































































































































































































































































































































































































































































































































































































































Fully methylated Half methylated Unmethylated
A
B
            Figure 23. The strategy for identifying the methylation status of CG 
dinucloetides in  FAT10 promoter.  
           (A) The mechanism of Methylation specific PCR (a)Unmethylated cytosine 
will be converted to uracil by treatment with bisulfite solution. (b). If cytosine 
C was methylated, it can not be converted to uracil by bisulfite treatment. 
Methylation Specific PCR was done by using primers specific to converted 
sequence. The methylation status of FAT10 can be known by sequencing the 
Methylation Specific PCR product. (B) Sequening results show that there are 
three kind of methylation status including fully methylated (1), half 









































T ● ● ● ◎ ● ◎ ● 12
N ◎ ◎ ◎ ◎ ◎ ◎ ◎ 7
T ● ○ ◎ ○ ○ ● ◎ 6
N ◎ ◎ ● ◎ ● ● ● 11
T ◎ ◎ ◎ ◎ ◎ ◎ ◎ 7
N ◎ ◎ ● ● ◎ ◎ ◎ 9
T ◎ ◎ ◎ ◎ ◎ ◎ ◎ 7
N ◎ ◎ ◎ ◎ ◎ ◎ ◎ 7
T ◎ ◎ ◎ ◎ ◎ ◎ ◎ 7
N ○ ○ ◎ ◎ ◎ ◎ ◎ 5
T ◎ ◎ ◎ ◎ ◎ ◎ ◎ 7
N ● ● ● ● ○ ● ● 12
T ○ ○ ◎ ◎ ○ ◎ ◎ 4
N ○ ● ○ ○ ◎ ◎ ● 6
T ○ ◎ ○ ○ ◎ ◎ ◎ 4
N ● ◎ ◎ ◎ ◎ ◎ ◎ 8
T ◎ ◎ ◎ ◎ ◎ ◎ ◎ 7
N ○ ● ● ◎ ○ ◎ ◎ 7
T ◎ ◎ ◎ ◎ ◎ ◎ ◎ 7
N ○ ○ ◎ ◎ ◎ ◎ ◎ 5
























Table 3. The methylation status of CG dinucleotides in FAT10 promoter 
in HCC patient tissues.  
CG1 to CG7 are CpG dinucleotide showed in the diagram in Figure 22. The 
first column shows paired patient number; The second column shows the folds 
of expression level of FAT10 in tumor tissue comparison to that in normal 
tissues.  
 
Scores:  ● denotes fully methylated site          (score=2) 
             ◎ denotes half  methylated site           (score=1) 
             ○ denotes unmethylated site               (score=0)  
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4.4  Discussion 
4.4.1  No mutations at the FAT10 Promoter were observed.    
Overexpression of FAT10 has been observed in HCC and gastrointestinal and 
gynecological cancers (Lee et al., 2003). High level of the FAT10 protein in cells was 
recently found to lead to increased mitotic non-dysjunction and chromosome 
instability (Ren et al., 2006). Therefore, one of the main objectives of our study was 
to elucidate the mechanism behind the aberrant expression of FAT10 in the tumor 
tissues of HCC patients. Since mutations found in the promoter region had been 
correlated with the overexpression of genes in cancer cells (Kanakis et al., 2003; Xu 
et al., 2004), we sequenced ~1.3kb of the FAT10 promoter region from tumor and 
adjacent non-tumorous liver tissues of 37 HCC patients to screen for mutations. 
However, no mutations were identified within the 1.3 kb region of the FAT10 
promoter suggesting that the difference in FAT10 expression levels between the HCC 
tumor and adjacent non-tumorous tissues cannot be accounted by mutations within the 
1.3 kb region of the FAT10 promoter. However, it does not rule out mutations 
upstream of this region accounting the differential expression between the tumor and 
adjacent non-tumorous tissues. 
Nonetheless, although no mutations were found in the tumor of HCC patients 
that may account for differential FAT10 expression between the tumor versus 
adjacent normal tissues, we identified polymorphisms in both the tumor as well as 
adjacent normal tissues of the HCC patients. As these polymorphisms are found in 
both the tumor and adjacent normal tissues, they cannot account for the differential 
FAT10 expression that was observed.  Nevertheless, these SNPs may affect the basal 
FAT10 expression and account for the differences in basal FAT10 expression 
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amongst different individuals. Polymorphisms in promoter of genes have previously 
been demonstrated to affect promoter activity and hence gene expression (Aklillu et 
al., 2003; Bond et al., 2004; Joosten et al., 2001; Sibley et al., 2003). Since high 
FAT10 has been associated with increased chromosomal instability (Ren et al., 2006) 
and chromosomal instability is one of the hallmarks of cancer, it raises the possibility 
that individuals with polymorphisms that result in high FAT10 promoter activity and 
expression may have higher risks of having cells with unstable chromosome number 
leading to higher risk of developing cancer.   
 A total of six polymorphisms were identified, of which two low frequency 
polymorphisms are novel. Two of the six SNPs were found to be monomorphic in 
normal individuals and occur at low frequency in the HCC patients. While 7 
haplotypes can be inferred from the 6 SNPs identified in the HCC patients, only 5 
haplotypes can be inferred from the 5 SNPs found in the normal individuals (Fig. 20).  
Three of the 7 haplotypes are found exclusively in HCC patients while one haplotype 
exist only in normal individuals (Fig. 20). Despite these differences, Fisher’s Exact T-
test showed no statistically significant differences between the SNPs or haplotypes of 
the HCC patients and normal individuals (P>0.05). As those SNPs and haplotypes that 
are different between the HCC patients and normal individuals occur at very low 
frequency, more samples need to be examined before a conclusion can be made.  
 From in silico analyses, all of the polymorphisms observed at the FAT10 
promoter either remove an existing, or introduce a new putative transcription factor 
binding site or change a putative binding site to another (Table 2). Experimentally, we 
demonstrated that different haplotypes of FAT10 polymorphisms resulted in 
significantly different FAT10 promoter activity compared to the wild-type.  
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Interestingly it seems that changing SNPs 3 and/or 4 generally result in lower FAT10 
promoter activity while changing SNPs 1, 2, and/or 5 generally results in higher 
FAT10 promoter activity.   The only exception is when SNP1 and SNP6 are changed 
simultaneously (haplotype CGTCAG) resulting in significantly lower FAT10 
promoter activity.  Although significant, the changes observed with the different 
haplotypes is less than 2 fold unlike the differential expression observed between the 
HCC tumor and adjacent non-tumorous tissues which can be more than 5 folds. These 
results suggest that although individuals with different FAT10 promoter haplotype 
may have significantly different basal levels of FAT10 expression levels, these 
differences may not be large enough to modify the risk of the individuals to develop 
HCC or have cells with different chromosome stability potential. This is consistent 
with our observation of no statistically significant differences between the SNPs or 
haplotypes of the HCC patients and normal individuals (P>0.05).   
 
4.4.2  Differential methylation may account for the differences in FAT10 gene 
expression between HCC tumor and adjacent non-tumorous tissues 
CG dinucleotides are present in the regulatory regions of many genes (Bird, 
1996). In normal cells, the cytosines in the CG dinucleotides generally remain 
unmethylated (Bird, 1996). However, in the promoter sequences of genes associated 
with certain cancers or inherited diseases, more cytosines at the promoter region were 
found to be methylated (Herman et al., 1996). The methylation status in the DNA of 
humans and other mammals play an important role in determining whether some 
genes are or are not expressed. Abnormal DNA methylation plays an important role in 
other developmental diseases as well. Abnormal increases or decreases in DNA 
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methylation are often observed in human cancers and may contribute to their 
development (Baylin et al., 1998; Herman et al., 1996).  
Seven CG sites were observed to reside in FAT10 promoter region. In order to 
study the correlation between the methylation status of these CG dinucleotides and the 
aberrant expression of FAT10 in HCC patients (Lee et al., 2003), we performed 
methylation-specific sequencing to screen the methylation status of these CG 
dinucleotides at the FAT10 promoter in 11 HCC patients. We found that generally, 
higher FAT10 expression is correlated significantly with reduced methylation of the 
CGs at the FAT10 promoter (Kappa value=0.468) (Table 3). The exceptions are 
patients 6, 10 and 11 whereby although the HCC tumor tissues has higher FAT10 
expression, the methylation status of the tumor is either more in the tumor (P6) or no 
different from the adjacent normal tissues (P10 and 11).   It is possible that differential 
methylation of other unexamined sites correlates with the FAT10 expression. A 
previous report demonstrated that methylation status in the coding region may also 
play a role in the regulation of gene expression (Irvine et al., 2002). Hence, it would 
be worthwhile to determine the methylation status of the coding region as well as 
regions further upstream the 1.5 kb promoter that we examined. 
In summary, although no mutations were identified at the FAT10 promoter in 
the tumor of HCC patients, polymorphisms at this promoter was identified which 
facilitated differential FAT10 promoter activities. Importantly, the methylation status 
at this promoter was found to correlate significantly with FAT10 expression levels.   
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Conclusion 
 
In order to elucidate the mechanism of the aberrant expression of FAT10 in 
liver tissues of HCC patients, we initially cloned and characterized FAT10 promoter. 
We found that the core promoter of FAT10 gene resides at the 5’ UTR and regions 
upstream of the 5’UTR did not confer any promoter activity. Interestingly, we found 
that FAT10 may be a downstream gene of p53 as it can be significantly repressed by 
p53. Results from Chromatin immunoprecipitation suggests that p53 represses FAT10 
by directly binding to its consensus site which resides upstream of the transcriptional 
start site in FAT10 promoter. We also found that the region between -975 and -1997 
bp upstream of the transcription start site may play a role in the response of FAT10 
promoter to TNF-α and IFN-γ cytokines. 
To elucidate the mechanism behind the aberrant expression of FAT10 in the 
tumor tissues of HCC patients, we sequenced the ~1.3 kb of the FAT10 promoter to 
screen for mutations and determined the methylation status of this promoter in HCC 
patients.  No mutations can be found in the tumor tissue of the FAT10 promoter that 
can account for the aberrant FAT10 expression. However, 6 polymorphisms were 
identified in this promoter. Haplotypes of these polymorphisms were found to mediate 
different FAT10 promoter activity. Significantly we found that the methylation status 
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